UNITED STATES OF AMERICA

CENTERS FOR DISEASE CONTROL

+ + + + +

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

63rd MEETING

+ + + + +

WEDNESDAY, JULY 29, 2009

+ + + + +

The meeting convened, at 9:00 a.m., in the West Chester III Ballroom at the Cincinnati Marriott North at Union Centre, 6189 Muhlhauser Road, West Chester, Ohio, Paul L. Ziemer, Chairman, presiding.

PRESENT:

PAUL L. ZIEMER, Chairman
JOSIE M. BEACH, Member
BRADLEY P. CLAWSON, Member
MICHAEL H. GIBSON, Member
MARK GRIFFON, Member
JAMES E. LOCKEY, Member
JAMES MALCOLM MELIUS, Member
WANDA I. MUNN, Member
ROBERT W. PRESLEY, Member
JOHN W. POSTON, SR., Member
GENEVIEVE S. ROESSLER, Member

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701 PRESENT: (Continued)

PHILLIP SCHOFIELD, Member
THEODORE M. KATZ, Acting Designated Federal
Official

REGISTERED AND/OR PUBLIC COMMENT PARTICIPANTS:

ADAMS, NANCY, NIOSH Contractor AL-NABULSI, ISAF, DOE BALDRIDGE, SANDRA BRADFORD, SHANNON, NIOSH BROCK, DENISE, NIOSH BROEHM, JASON, CDC DOLL, LOU, BTNMSP GILL, JANICE, Fernald Worker HINNEFELD, STU, NIOSH HOWELL, EMILY, HHS KOTSCH, JEFF, US DOL MAKHIJANI, ARJUN, SC&A MAURO, JOHN, SC&A McFEE, MATT, ORAU Team MEDL, EUGENE, Fernald (Retired) PRESLEY, LOUISE RAFKY, MICHAEL, HHS ROLFES, BETH, NIOSH ROLFES, MARK, NIOSH RUTHERFORD, LaVON, NIOSH ZIEMER, MARILYN

C-O-N-T-E-N-T-S

Welcome4 Chairman Paul Ziemer
SEC Petition Status Update5 LaVon Rutherford, NIOSH
Subcommittee, work group Reports
Board Working Time
Board Working Time
Adjourn

P-R-O-C-E-E-D-I-N-G-S

9:16 a.m.

CHAIRMAN ZIEMER: Well, good morning, everyone. We will be ready to begin our deliberations on this third day of the Advisory Board meeting here in the Cincinnati area, more specifically West Chester, Ohio.

I will begin with my usual reminder to register your attendance with us this morning in the foyer if you have not already done so. Again, copies of the agenda and related documents are on the table in the rear of the room.

We are going to begin this morning with kind of what I think of as our heads-up report. It's SEC status and SEC petitions that are coming down the line or are in process. And LaVon Rutherford will give us that update.

Good morning, LaVon.

MR. RUTHERFORD: Good morning, Dr. Ziemer. Thank you.

As Dr. Ziemer said, Lavon Rutherford, Special Exposure Cohort Health Physics Team Leader for NIOSH, and I will give the update on SEC petitions.

We do these at each Board meeting to give the Advisory Board information on the current number of SEC petitions we have, their status. It allows them to prepare for future work group sessions and also prepare for future Board meetings.

As of July 7th -- and I think this number has already increased -- we are at 148 petitions. We have seven petitions that are in the qualification process. We have qualified 83 of those 148. We have four evaluations in progress at this time. And we completed 79 Evaluation Reports. There are 58 petitions that did not qualify. And we have 20 petitions that the Board is acting on.

SEC petitions currently in the evaluation process: Brookhaven National Lab, as you have heard at a previous meeting, we

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

have had difficulties through data capture, some PII information issues, a little funding issues at times, but we do believe that that is coming to closure and that we should issue that report sometime in August and be ready to present that at the October Board meeting.

United Nuclear Corp., we had completed that evaluation. However, during the evaluation process, we had made recommendation to the Department of Labor that we believe the current covered period should be extended to 1973. We decided to pull that evaluation back to add the additional years in once the Department of Labor concurred and added those years. We decided to pull that evaluation back and do that.

So we are in that process at this time. We anticipate completing that Evaluation Report in August and presenting it at the October Board meeting as well.

Piqua Organic Moderated Reactor, very similar situation. During our

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

evaluation, we looked at the covered period.

And the petitioner had actually petitioned for an extended period.

And in our review of that extended period, we recognized that D&D was not included in the current covered period. We provided the information to the Department of Labor. And that covered period was extended.

So we pulled that Evaluation Report back. We are currently in the process of adding that portion of the evaluation to the report. We anticipate completing that in August and presenting that at the October Board meeting as well.

University of Rochester. We received that petition on March 6th. And we are on schedule to complete that report in September.

I do believe that report will be completed in time. That will give the Board and the petitioners adequate time for review to present that at the October Board meeting.

NEAL R. GROSS

So we have University of Rochester, Piqua, United Nuclear, and -- what was it? -- Brookhaven National Lab are four that we anticipate presenting in October as well as which are not on the -- my slides, at least two 83.14s. And one of those will be for metals and controls, and the other one -- and I will discuss briefly -- will be Hanford.

SEC petitions that are with the Board for recommendation, Chapman Valve, we believe all of our NIOSH actions are complete with this one. Blockson Chemical. Blockson Chemical was discussed at yesterday's meeting. Ι think there is going to be further discussion this morning during the work group updates.

Fernald Feed Materials Production

Center, there is research and discussion

ongoing with this one. There are few

remaining issues.

Bethlehem Steel. NIOSH's actions we feel are complete with Bethlehem Steel.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

And the petition and report are with the Work Group.

Hanford. Hanford has been on our plate for a while. There were a number of issues identified by SC&A. We have worked through a lot of these issues. However, we have come to a position that we believe that resolution of those issues will resolved by doing an 83.14 to extend existing class. And then in parallel what we will do, we will be doing a TBD revision that will include what work we believe we can do out of that period from the 83.14.

So we anticipate the 83.14 being complete and ready for the October Board meeting and the TBD revised and claims completed shortly thereafter.

Nevada Test Site. The Work Group is down to a few remaining issues. That work is still ongoing.

Mound plant. I believe Ms. Beach gave an update earlier in the meeting.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Research and discussion continue.

Texas City Chemical. We are currently revising the existing Evaluation Report to include some documentation that we received right at the time we had issued Revision O. We anticipate completing that and issuing that Evaluation Report very soon.

Santa Susana. There is still research and discussion ongoing with the Work Group.

Dow Chemical, we had a Work Group meeting on this past Friday. SC&A is going to take a look at the Appendix C, which incorporated NIOSH's addendum to evaluation of Dow Chemical to see how we incorporated that into Appendix C. And so there is still a little work left there.

Pantex. Research and discussion continues with Pantex as well as Savannah River site.

General Steel Industries, there is a little bit of work going on still with

General Steel Industries with Work Group.

Los Alamos National Lab, again, research and discussion continues.

Linde Ceramics, SC&A just recently completed their review of the NIOSH evaluation. There is a work group tentatively scheduled for the end of this month or the first of next month. Dr. Roessler is working on that. And I think at that time we will also present the actual evaluation to the Work Group.

Bliss and Laughlin. We had anticipated that we would be presenting this at this Board meeting. We had completed our report and sent the report out. However, and, you know, we did not get that report out as quickly as we wanted.

The petitioner did ask if we would postpone presenting that petition. They talked to the Designated Federal Official.

And we will present that petition at the October Board meeting. This will give the

petitioners a little more time to review it and also give the Board a little more time as well.

Baker-Perkins. We presented that report at the Board meeting yesterday. And the Board concurred with our recommendation.

Lake Ontario Ordnance Works. We presented this report at the Board meeting yesterday. And the Board concurred with our recommendation.

Oak Ridge Hospital. We presented the report at the Board meeting yesterday. However, the Board has recommended a little more review. And they wanted to get back and verify that we had actually pulled all of the strings to look for information at Oak Ridge Hospital. And I believe that there will be further discussion on that today and a work group established.

Norton Company. We presented our Evaluation Report at the Board meeting yesterday. And the Board concurred with our

NEAL R. GROSS

recommendation.

And that's it. Questions?

CHAIRMAN ZIEMER: Very good, LaVon.

Let's ask if anyone has comments or questions for LaVon.

(No response.)

CHAIRMAN ZIEMER: We appreciate the regular summaries to help us stay on track. The number of SECs is expanding, and it is helpful to track them in this way. So we appreciate that.

While we are looking at the SECs and we are just slightly ahead of schedule, I think it would be a good time just to take the wording from the actions that LaVon just referred to.

And we have distributed to the Board members and also to the NIOSH staff, to counsel, and to Labor the proposed wording of the letters that would go to the Secretary concerning Baker-Perkins, Lake Ontario Ordnance, and the Norton Company.

And if you would take those right now, I think it would just be a good time just to make sure that we have the wording. The motions have already passed. And we simply need to confirm that the wording is as it should be.

Most of this, Dr. Lockey, who was an apprentice to Dr. Melius on the wording yesterday, and took that burden to actually do the wording.

And, Dr. Lockey, did you have any final changes after your mentor had a chance to look at these and correct you?

MEMBER LOCKEY: I hadn't had a chance to talk to Jim, but we have a female Secretary now. And I changed the wording in the first paragraph. And I looked at it again last night, and the wording had to be for our distinguished Chair, Paul. So it has to be changed back from she to he. That is the only correction I have. That is in the first --

CHAIRMAN ZIEMER: Which one is

NEAL R. GROSS

1	this?
2	MEMBER LOCKEY: First paragraph.
3	CHAIRMAN ZIEMER: Of which letter?
4	MEMBER LOCKEY: Both letters.
5	CHAIRMAN ZIEMER: Oh, both letters?
6	MEMBER LOCKEY: Yes.
7	CHAIRMAN ZIEMER: Well, both
8	meaning the Norton letter
9	MEMBER LOCKEY: And the Lake
LO	Ontario.
11	CHAIRMAN ZIEMER: and the Lake
L2	Ontario letter.
L3	MEMBER LOCKEY: Third sentence,
L4	last word. And I will change that on the
15	draft. This should be the
L6	CHAIRMAN ZIEMER: Yes. It's the
L7	third line. The Board requests that he,
L8	referring to me.
L9	MEMBER LOCKEY: Yes, that's
20	correct.
21	CHAIRMAN ZIEMER: He. So that
22	would be a change on the copy of the Ontario

1	letter that you have.
2	MEMBER LOCKEY: And the Norton
3	letter.
4	CHAIRMAN ZIEMER: Same change on
5	the Norton letter.
6	MEMBER LOCKEY: Correct.
7	CHAIRMAN ZIEMER: Thank you.
8	So let's look first at the Lake
9	Ontario. The first sentence is actually or
10	the first paragraph is not part of what goes
11	to the Secretary, of course. This is the
12	formal recommendation charging the Chair to
13	move this document out.
14	The letter to the Secretary would
15	begin with the second paragraph, which
16	indicates that the Advisory Board has
17	evaluated this SEC this is sort of
18	boilerplate language and that we recommend
19	something, in this case that they become a
20	Class of the Special Exposure Cohort.
21	We identified the facility and the

That is, this is the description of the

time.

Class. And it is particularly that description that we want to make sure the words are okay with NIOSH and Labor and counsel.

And then we have several bullet points, in each case indicating the basis for the recommendation, and then the final paragraph, which refers to the deliberations at this meeting and various materials that will be provided to the Secretary as backup information.

So this is the usual form of the letters. Board members, are there any comments on wording or any editorials that you believe need to be made? Let me ask first about Lake Ontario. We are not going to take any formal action because we have approved the motion and simply want to make sure the wording is okay.

I will also ask both Labor and OCAS and counsel, are we okay on the wording or any questions? Okay. I am pausing here for a

NEAL R. GROSS

speaking with 1 moment. Mr. Hinnefeld is 2 counsel. And that makes me a little nervous. Larry Elliott? 3 MR. HINNEFELD: Norton is an Atomic 4 Weapons Employer. And the wording here is the 5 6 stock wording for a DOE facility in the Norton So it should say things like AWE 7 employees, instead of DOE employees. 8 And subcontractors would not be included. 9 10 CHAIRMAN ZIEMER: Yes. MEMBER LOCKEY: Yes, talked 11 we about that yesterday. And it says, let's see 12 13 -- its predecessor agencies. Does that cover --3 14 15 MR. HINNEFELD: No, predecessor 16 agency would be the Atomic Energy Commission or the Manhattan Engineering District. 17 MEMBER LOCKEY: Okay. 18 19 MS. HOWELL: Ιf Ι could just suggest that you use the wording from 20 actual NIOSH SEC Evaluation Report from the 21 I'll show you my notebook if you don't 22 Class.

1 have it in front of you because the wording for DOE that is used for Lake Ontario is a 2 little different than Norton. 3 4 CHAIRMAN ZIEMER: Right. MS. HOWELL: So, rather than just 5 switching out the words, actually. 6 7 CHAIRMAN ZIEMER: I think you can go to the slide presentation that was made or 8 go to the Evaluation Report. That will be 9 10 That's just for Norton, I believe. MS. HOWELL: I mean for both of 11 them but specifically Norton. 12 CHAIRMAN ZIEMER: So in the second 13 sentence of the second paragraph, it would 14 15 read, the Board respectfully recommends 16 Special Exposure Cohort status be accorded to all AWE employees who worked at the Norton 17 Company in Worcester, Massachusetts 18 19 January 1st, '45 through December 31st, '57 and then the rest of the material. So we will 20

NEAL R. GROSS

ELLIOTT:

accept that as the correct wording.

MR.

21

22

And Lake Ontario

1 Ordnance Works, I don't see any corrections to 2 be made to that definition. But I will await counsel's --3 That's just 4 CHAIRMAN ZIEMER: Yes. the Norton. Is that correct? Yes. 5 6 MR. ELLIOTT: Just Norton. CHAIRMAN ZIEMER: We will make that 7 change. Are there any others on either Norton 8 or Lake Ontario? 9 10 (No response.) CHAIRMAN ZIEMER: Ιf not, those 11 will be the documents that will go forward. 12 The third one is the document where NIOSH has 13 could determined that it do dose 14 15 reconstructions with sufficient accuracy. This is for the 16 Baker-Perkins Company in And that letter is still a draft, 17 Saginaw. although since we using previous 18 were а 19 template, it also shows up our normal on letterhead. 20 It does not have the usual leading 21

paragraph that instructs the Chairman to send

this forward within 30 days, but I understand that that is part of the intent.

So this is actually what the letter would look like. And it is a little different than the others in that it simply says NIOSH has recommended that these workers not be added to the Special Exposure Cohort, but NIOSH has determined that it has access to adequate exposure monitoring, other information to do dose reconstructions with sufficient accuracy. And then it simply says the Board concurs.

We do supply supporting information, which basically are the transcripts of the meeting that available for backup material. We have not had many letters like this that have gone to the Secretary, but this is the format that has been used where a Special Exposure Cohort is not recommended.

Again, there is no class description here since no SEC is being

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

recommended. It simply refers to the petition and the fact that NIOSH and the Board concur that dose reconstruction can be done with sufficient accuracy.

Any editorial changes or comments on the final product here?

(No response.)

CHAIRMAN ZIEMER: If not, we will consider those approved. Good. That was actually part of the Board working time that we used since LaVon gave us some additional minutes there. So now we will return to the regular schedule.

The next item is the subcommittee and work group reports. And we will go through these. If your subcommittee or work group has particular actions or issues that you wish to report to the Board or actions that need to be taken, we ask that you do that, chairs of the Subcommittees and work groups.

If you have nothing to report, you

NEAL R. GROSS

1 can just so indicate. And those that have 2 already reported, for example, Mound, we had an extensive report. So it's not necessary 3 that we do anything further unless the chairs 4 themselves want to add additional information. 5 So we do know that in a couple of 6 7 cases, there are some specific things, such as for the Procedures Work Group. And I would 8 suggest that we start with that, Ted. 9 And 10 then we can pick up. This is the Procedures Subcommittee now. 11 will do the And then we 12 13 Reconstruction Subcommittee separately because we have a time set forth for that later. 14 So we will do the Procedures Subcommittee and 15 then the other work groups. 16 Wanda Munn, if you are prepared to 17 proceed, why, we will go from there. 18 19 MEMBER MUNN: I am sorry. I was carrying on a sidebar conversation. 20 you are talking about Procedures? 21

NEAL R. GROSS

CHAIRMAN ZIEMER:

22

Well, we hope we

were.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

MEMBER MUNN: That's very good.

CHAIRMAN ZIEMER: And I think you were going to present something on the CATI today --

MEMBER MUNN: Yes, as a matter of fact.

CHAIRMAN ZIEMER: -- and anything else that your subcommittee wishes to report.

MEMBER MUNN: Before I begin that report, I would like to make sure that all of the members of the Board do indeed have the material, the CATI material, that was forwarded to you by email on the 20th, I believe. So that you would have had adequate opportunity by now to look through that so that you would see what changes our Procedures group had suggested in collaboration with our interactions with NIOSH and with our contractor over an extended period of time.

We have worked on that correction, those corrections, in order to try to make the

interactions with our claimants more easy and more comforting for the claimants, rather than create a stress issue for them.

If it's all right with you because that will require, I suspect, some discussion among the Board, I would like to address that issue at the very end of our other comments. That way we can go through a quick review of what the Procedures Review organization has been doing since you last heard from us and postpone our discussion to the end of the comments.

The Subcommittee met on June 9th and spent a significant portion of our time working on that CATI issue. Our second issue that we have pending before us right now is a discussion relative to a status report to the Secretary.

Procedures has only given the Secretary one report during the history of our organization here, and it was the general feeling of the Subcommittee that it was time

NEAL R. GROSS

to make another report to the Secretary.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

What that will contain is an overview of what has transpired since previous letter, which was more than a year During the period of time that we have been doing this -- we are right now dealing with the change in the operating system of the database that we work with. And it is closely tied in with the computer activities that we have been having so much grief with the last day or two but now appears to be resolved.

So the end of this week, we expect the entire database that we use to be of the same format but completely different operating system, which will be commensurate with an electronic system that we are using individually.

That status letter we hope to have drafted and be ready for our next subcommittee meeting, which is coming up next month. It is our intention to have that draft in your hands at our next face-to-face Board meeting so that

if you have any concerns with respect to that report, you will be able to tell us about it.

of the things that One our contractor has done for us during the last two that have had is provide meetings we progress report of where we are in not only numerical spreadsheet format but also graphic format.

And I have loaded that graph on the computer up here. I would like to show it to you for just a minute. I think most of you will agree that graphs serve an enormously effective purpose in conveying information to individuals who are not always enthusiastic about spreadsheet presentations and numbers.

These will give the information to all observers in two ways. One, a straightforward numerical review of what the numbers are as we go along from over the last period the changes that have been made.

I may need to get up to read that myself since I don't have it on my screen.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

CHAIRMAN ZIEMER: Maybe we could also expand that in terms of the zooming in a little further and then put the single page up if that is possible.

MEMBER MUNN: Yes. It should zoom. There we go. Now you can read what the colors represent. Thank you. The first one, as I indicated, will be the status of the procedure reviews in numerical form only, red being the open items that we have, the in progress, the magenta orange other format in addressed in some procedures than the one where the binding was originally indicated.

The aqua is our transferred material, which will go from one work group, our Procedures Subcommittee, to another for reasons having to do primarily with the focus of that particular procedure.

The purple is indicating what we have in abeyance, which essentially means we are holding that awaiting further action or

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

additional information from some other resource. And the blue shows the number that are closed.

As I indicated, that is pure numerical information. The other that we intend to provide is the status in terms of percentage of issues, which is another way to look at what we are doing.

Regardless of which of these you see, I believe you will see that we are making progress. We have over 500 individual findings with which we are dealing.

Some of them are relatively simple and simply have not been addressed thoroughly yet. The others are extremely complex and take a great deal of effort on the part of both the Subcommittee, the agency, and the contractor.

So we are getting there. But it will change from month to month as we occasionally have the Board recommend additional material that they would like us to

NEAL R. GROSS

1	review and as we clear things from this
2	particular
3	CHAIRMAN ZIEMER: Wanda, I am not
4	seeing it very well from here, but is what you
5	call blue the bottom part of the bar?
6	MEMBER MUNN: The bottom part of
7	the yes. That is our closed items.
8	CHAIRMAN ZIEMER: Okay. Yes. So
9	the number is close to 50 percent now. Is
10	that correct?
11	MEMBER MUNN: It is pretty close to
12	50 percent if you use the closed and in
13	abeyance figures. In abeyance is something
14	that we as a subcommittee can't do anything
15	about together. Then it comes to about 50
16	percent. That is correct.
17	I can read you the numbers of the
18	most recent spreadsheet that we had, but I
19	doubt that that will
20	CHAIRMAN ZIEMER: And I have those
21	numbers. I simply wanted to clarify what the
22	closure value was on these issues. And the

colors often look a little different from this angle at least. I may be colorblind as well.

MEMBER MUNN: Well, it always depends on the screen and the presentation itself. I am going to leave that up. It is not unusual for us to have a situation where it is necessary for us to have technical calls in between our meetings.

Quite often we find that the individual findings with which we are dealing boil down to such technical specifics that it is impossible for anyone other than the health physicists themselves to work out an agreement and come to a resolution.

We had such a situation this last month where we had two outstanding issues with OTIB-0029. We had dosimetry and coworker data issues there, two different findings that needed to be resolved. We did have that telephone call. The issues were, I believe, satisfactorily resolved will and recommended for different status at our next

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

meeting.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

We are also in the process of asking our contractor to prepare for us a list of commonality of findings. As you probably are aware from the years of our having gone through these things, from one site to another, there are many findings that recuragain and again.

We have tried to identify those in the past and put them into a pool that we call various We started out with names. over-arching issues. And I think we now have a different terminology that we use. But our contractor has been tasked with the work of identifying those outstanding issues that we have from our multiple procedures, all of which essentially are the same finding, just in a different set of procedures.

And so we are going to try to identify those so that we can remove those from the list we have, which would be very helpful for all concerned since they will be

probably not always complex-wide but certainly repetitive kinds of issues that can be addressed with a single finding.

We are preparing a very simplistic template for the transfer of findings or the transfer of I should say full responsibility for full procedures that are outstanding from one group to another.

You can understand how that would occur from time to time. And we have come to the conclusion our best option and the most simplistic way for doing that is to transfer them by email with copies to all of the members of the Board so they know when responsibility has gone from the Subcommittee to a work group or vice versa.

We will be in the process of transferring OTIB-0058, which is external coworker dosimetry data for the Rocky Flats plant, to Mark Griffon's work area.

And I will have that transfer template, as it were, ready to make that

NEAL R. GROSS

change before our next work group meeting. We will then decide if that is acceptable as a method for transferring from one responsibility level to another.

If anyone on the Board has any grief with that method, if they feel that it needs to be much more formalized than that or if they feel it is inadequate in any way, please let me know.

This brings us, I believe, to the issue of the CATI. The Computer-Assisted Telephone Interview has been of concern to a great many people for quite a number of months, if not years, and we have been working on it for several months.

We believe that the material that we sent to you earlier now constitutes our best effort. We believe we have removed from that process if not all, then certainly the vast majority of the types of questions or wording of questions that was creating concern for the claimants, many of whom mistakenly

NEAL R. GROSS

believed that they were going through some kind of test when we were asking them to complete these forms.

If any member of the Board has any comment with respect to the material that we have placed before you, we would certainly like to have that discussion now because it is our intent to direct NIOSH to take the document that we now have in hand for them, to take whatever steps are necessary to make it our official CATI document.

CHAIRMAN ZIEMER: insert Let me here that these are, in essence, NIOSH I always want to be a little documents. careful in terms of what our prerogative is relative to sort of NIOSH's business.

As I look at the CATI interviews and the letters, I think -- and NIOSH has asked for the Board's input. I don't think we are directing them to do something, but we are suggesting changes that we think would be helpful.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

I want to put it in that framework because I don't believe it is our prerogative to direct NIOSH's work. And the CATI interviews and the letters are in a sense, I guess, work products that NIOSH uses.

But, nonetheless, in our role as sort of an interface with the public and with NIOSH, NIOSH has certainly asked for our input. And so we want to frame it in that way. And so we are not approving something for NIOSH's use so much as suggesting what we think might be improvements.

And so when we in a sense ask for the Board's concurrence on some revisions, these are revisions, first of all, that, based on discussions in the Procedures Subcommittee, that NIOSH has developed. They have developed this wording. And basically we are working together on it.

I just want to frame it out in terms of our roles and make sure that you understand that we are not directing so much

NEAL R. GROSS

1	as recommending.
2	Dr. Melius?
3	MEMBER MELIUS: Mark was actually
4	
5	CHAIRMAN ZIEMER: Oh, Mark, did you
6	have a comment?
7	MEMBER GRIFFON: I wasn't sure if
8	you wanted to do these in a certain order, but
9	I have the EE questionnaire up, as opposed to
LO	the survivor one.
11	CHAIRMAN ZIEMER: Yes. And let's
L2	make sure everybody knows there are two sets
L3	here. There are two different cover letters
L4	depending on whether it is the worker or the
L5	survivor that is the claimant. And then there
L6	are two sets of interview
L7	MEMBER GRIFFON: Questionnaires,
18	yes.
L9	CHAIRMAN ZIEMER:
20	questionnaires. So there are actually four
21	separate documents. And these are identified.
22	One is called the EE cover letter. And the

1	other is the EE questions. And the other one
2	is the SB.
3	MEMBER MUNN: Standing for
4	survivor.
5	MEMBER GRIFFON: That is the
6	survivors.
7	CHAIRMAN ZIEMER: Or SB, the
8	survivor letter and the survivor questions, so
9	those four documents.
10	MEMBER GRIFFON: And I was in the
11	Subcommittee process. So I did have some
12	input into this. There is one little one that
13	I wanted to note on 19.11, question 19.11, of
14	the questionnaire, the energy employee, the
15	EE. It says, did you receive chelation
16	therapy or other medical treatment as a result
17	of radiation exposure from this incident?
18	And then it says, yes, chelation
19	therapy. I think it says, chelation therapy
20	or other medical treatment. And then the only
21	yes option is, yes, chelation therapy.

So I am not sure why that was added

in. It seems like it maybe should be, yes, chelation therapy or, yes, other, or something. I don't know. That is a minor thing, though. I just wanted to note it because it is a new edit, it looks like.

And my bigger concern is this one was discussed at length the Procedures Subcommittee -- the last question at the bottom. This is getting back to the coworker thing. I asked that we still include And I think I am okay with this question. NIOSH putting sort of a qualifying line in the front that -- which is there already.

It says, NIOSH is confident it will obtain enough information to complete your dose reconstruction without receiving information from other individuals. However. But it's the however part that I think there should be a however and then have a yes/no option and then still have the, if yes, list the names and contact information because it is almost like, you know, don't list the names

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

here. We will call you if we need some coworker information.

And I think it might be useful for other reasons because I can see a situation where a lot of the workers list the same radiation contact person. They really trusted this guy. He knew his stuff. He was in the field all the time. And you start to query, although there is another whole level of questioning here with Larry and me.

But if you look through all of the questionnaires from, say, K-25 and you start to see this one guy pop up like 20 times listed as a contact person for exposure issues for people, I think, you know, SC&A, NIOSH might say, you know what? We haven't talked to -- you know, this guy might be somebody to interview about the overall rad operations and, you know, might help us shed some light on a certain topic.

So I think there is value in collecting those. I think qualifying it up

NEAL R. GROSS

front so there is not that expectation that, you know, when people -- I understand your concern that if people come back and say, I gave you four names, and you never contacted any of them, you know.

I think qualifying it is fine, but I think you should still include the section to allow them to list the names if they have the main contact information if they have it. So that is just my opinion on how to word that section.

CHAIRMAN ZIEMER: Thank you. And, actually, the original concern was what you described, that people typically have fed back to us the idea that they have provided these contact names and they have not been contacted.

With regard to your first comment, Mark, on 19, on the chelation therapy, I note that below that, they do give the option that you describe.

So it would appear that there would

NEAL R. GROSS

be no reason to put the chelation therapy there under 19.11 because 19.12 says, if your answer was no, skip ahead. If it was yes, then you tell us whether it's chelation or other.

So you're right.

MEMBER GRIFFON: It's a little odd.

CHAIRMAN ZIEMER: It looks a little odd under 19.11 since 19.12 actually resolves that issue so you don't need it in 19.11.

Dr. Melius?

MEMBER MELIUS: I have a few comments. Actually, the main thing is a question. First of all, in response to Mark's comments, I would also remind us that many of these people are elderly. And dose reconstruction does take some time.

And so often they are either more ill, you know, they have cancer and are unable to answer, provide information at a later point in time in the dose reconstruction process. So it seems to me collecting it

NEAL R. GROSS

earlier may be better.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Now, it may need to be supplemented or there may be more specific information needed, but it seems to me it would be useful to collect that information at the earliest possible time in the process while people have gathered as much information as possible and are still capable of responding.

I guess my second issue -- I don't want to elaborate. I don't think we need to elaborate on it, but I do think we're charged with reviewing dose reconstruction. It is being done.

certainly individual And dose reconstruction, certainly commenting on interview, you are right. We don't write the interview. We don't direct NIOSH to change it, but we are certainly well within our authority. And Ι think we have responsibility for providing comments in this situation and are asked to.

The question I have -- this is like

NEAL R. GROSS

1 -- this has taken some time, understandably. 2 But I am trying to get sort of caught up with the process where NIOSH is with doing these 3 revisions. 4 I think when we first started, it 5 was about to go to OMB. And NIOSH has, I 6 think appropriately, delayed that and move it 7 through our process first. 8 But I am just trying to understand 9 10 what happens now. We give comments, these comments, to NIOSH. What happens from here 11 forward? 12 13 MR. ELLIOTT: We have an extension from OMB to use the current questionnaire for 14 15 both claimant and survivors. 16 MEMBER MELIUS: Right. MR. ELLIOTT: And this allows us 17 time to hear your comments, hear your input, 18 19 and consider it. And then we go back to OMB. And as soon as this concludes, this process 20 concludes, and we understand what your input 21

is, then we can go back to OMB with our

1 proposed revision to the instruments and get 2 their clearance on those. That is what we are waiting on. 3 So the immediate 4 MEMBER MELIUS: process will be that we will provide these 5 6 comments to you. You will respond to the 7 Subcommittee or how is that? What happens specifically next? 8 Well, I think we can MR. ELLIOTT: 9 10 respond to the Subcommittee or we can respond to the full Board, however the Board wants to 11 I think the full Board see this conducted. 12 13 has an interest in this, but certainly the Subcommittee has spent a lot of time 14 and 15 discussion about it. 16 But yes, we would react to the body and explain how we handled, how we addressed 17 or why we didn't incorporate a change. 18 19 MEMBER MELIUS: In my mind, this 20 CHAIRMAN ZIEMER: has moved from the Subcommittee as of today to 21

the full Board because the Subcommittee is

1	bringing this as a recommendation and getting
2	the additional input.
3	So it would seem to the Chair that
4	the final document unless the Board so
5	charges, would come back to the Board because
6	it would be our action at this point.
7	And Larry would basically bring a
8	document and say, here is what we are sending
9	forward. And I don't think we want to keep
10	extending this process.
11	MEMBER MELIUS: Oh, no. That was
12	my
13	CHAIRMAN ZIEMER: They have been
14	very gracious in awaiting these comments. And
15	so we want to bring it to closure.
16	MR. ELLIOTT: I would offer this,
17	that we go back to OMB with revised
18	instruments. These are the questionnaires.
19	At that point, there is opportunity for public
20	comment on them again.
21	So you as individual members of the
22	public and/or as a Board can come back again

and say, we made a comment. They didn't take it or, now we have had another chance to look at it again, and we think this. So you still have another opportunity at the OMB approval process.

CHAIRMAN ZIEMER: Go ahead.

MEMBER MELIUS: Yes. Then my suggestion would be that we get this to NIOSH as quickly as possible. I would be willing to approve it today. And then see what the NIOSH comes back to us with.

There are points that need further discussion at the next Board meeting or even the next Board conference call, try to do it then and then expedite it to the extent that we can. I mean, if there are just sort of minor things, I don't think we need to delay.

CHAIRMAN ZIEMER: Right. And, actually, the intent here was to get Board action today to do just that. And the other items, such as Mark raised, in my mind are not items that we need to take formal action on.

NEAL R. GROSS

Rather, I would consider them to be sort of friendly amendments that NIOSH has heard. And I don't think we need a formal vote on every item.

Stu?

MR. HINNEFELD: I just wanted a little assistance in resolving Mark's comment.

Mark, the comment relating to 19.1 we can resolve. I think we --

CHAIRMAN ZIEMER: That is very easy. You just strike that, take the thing back out.

MR. HINNEFELD: The comment with regard to number 22 you said -- I'm not exactly sure where your comment ended. What change to 22 would satisfy your comment?

MEMBER GRIFFON: I would just add onto the bottom. Maybe it's just because it's kind of at the bottom of the page, but I would add on the bottom, after the question mark, put a yes or no option, just like you had before. And then, if yes, please list the

NEAL R. GROSS

1	names.
2	MR. HINNEFELD: So, in other words,
3	okay. So it says, can you readily provide
4	names, which I kind of took like we would put
5	some blank lines down here and they
6	MEMBER GRIFFON: Yes. The way it
7	read here was like, you know, we just want to
8	know if you can.
9	MR. HINNEFELD: If you can, we
10	might call you back.
11	MEMBER GRIFFON: We might call you
12	back.
13	MR. HINNEFELD: Okay. Got it.
14	MEMBER GRIFFON: But I would rather
15	have a listing.
16	MR. HINNEFELD: So we could put
17	yes/no and then, if yes, just have some blank
18	lines.
19	MEMBER GRIFFON: Right, right.
20	MR. HINNEFELD: Okay.
21	MEMBER GRIFFON: The only other
22	thing I would say in there is and this is

definitely a friendly amendment, but it says, provide names and contact information for coworkers and industrial hygienists. I would say radiation safety specialists and supervisors, you know, --

MR. HINNEFELD: Got you.

MEMBER GRIFFON: -- just to be complete there, I guess.

Want to remind the Board members who were not on the Subcommittee and may not have been as close to this is that this questionnaire is not filled out by the claimants. It is sent to them in advance to give them a head's up on what will be asked on the phone interview. So the interviewee has a great flexibility.

For example, it makes no difference if there are four lines there to fill out or five or ten, but the interviewee can extract as many names as the person wants to and, in fact, has the capability of even asking, you know, are there other people who don't have to

NEAL R. GROSS

even be listed.

I believe they have a fair amount of flexibility once this is approved. You know, it doesn't have to be the category of a radiation safety specialist or industrial hygienist. It is anyone the person wants to name. So there is additional flexibility on the part of the interviewer.

So this document goes to OMB to get the kind of information before OMB that will be asked of the public, but the interviewee does not fill out a form and send it back.

Did you have additional comment on that or --?

MEMBER GRIFFON: No.

CHAIRMAN ZIEMER: Okay. Wanda, did you have a comment on it?

MEMBER MUNN: Just one.

CHAIRMAN ZIEMER: Oh, the other thing is I don't believe the letter goes to OMB, only the questionnaire. Is that correct? So the letter is completely within NIOSH's

NEAL R. GROSS

1 prerogative in terms of the final product. 2 But what we would want -- is there something similar on the other interview? 3 4 Okay. 5 MEMBER GRIFFON: Yes, the same comment would apply for the survivor. That 6 7 question is still listed as 22, but I think the numbering is going to change because there 8 are other questions that are missing, yes. 9 10 But it is on the bottom. CHAIRMAN ZIEMER: So, let me ask if 11 there are other comments or recommendations on 12 13 either of the questionnaires or at the letters that would accompany them as far as what the 14 15 claimants get. 16 If there isn't, we can ask for a motion to recommend that NIOSH consider these 17 recommendations as they prepare **OMB** 18 the 19 documents. And we could do this as motions or as a group motion. 20 I will ask for it as a group motion 21

assembly wishes

unless

the

22

the

to divide

motion.

MEMBER PRESLEY: So moved.

CHAIRMAN ZIEMER: The motion is to recommend to NIOSH that these proposed changes be included, including those that were discussed here this morning. Is there a second?

MEMBER GIBSON: Second.

CHAIRMAN ZIEMER: Is there a discussion? And, Madam Chair, do you have additional comments on the documents that you wish to make before we vote?

MEMBER MUNN: Not really, only to thank you for clarifying that the claimants are not expected to fill these forms out and to add that the people who conduct the interview have been trained to make every effort to be as flexible as possible in achieving the end, which is desired to be as much complete information as the claimant can provide without undue stress.

With respect to the discussion that

NEAL R. GROSS

we just had about the wording of item 22 and 1 2 others, there was a great deal of time spent negotiating words and discussing the fact that 3 the terminology that we currently use today is 4 not always the terminology that was familiar, 5 especially to older workers. 6 That being the case, we have tried 7 language that could be 8 generally to use interpreted, not only in today's world but as 9 10 having some context in 1945 as well. It was I think the intent of the 11 subcommittee bring 12 entire to this 13 recommendation from the Subcommittee. So thank you. 14 15 CHAIRMAN ZIEMER: Other comments? Yes, Josie? 16 I just want to be 17 MEMBER BEACH: clear. Are we going to vote on all four? 18 19 CHAIRMAN ZIEMER: Yes, unless you wish to divide them. I think if a Board 20 member has an issue with a particular one, 21

that we would divide the motion. Otherwise we

1	would do it as a single motion.
2	MEMBER BEACH: I guess then I would
3	look at the copy of the if the claimant is
4	a family member and going back to what Mark
5	had addressed in the other on the
6	CHAIRMAN ZIEMER: Yes. This would
7	be the survivor.
8	MEMBER BEACH: I just wonder if we
9	want to incorporate putting in the names on
10	that one as well.
11	CHAIRMAN ZIEMER: Yes. I think
12	Mark had
13	MEMBER BEACH: Did you cover both?
14	I'm sorry. I missed that, then.
15	CHAIRMAN ZIEMER: Yes. He
16	suggested that. And I think Stu made a note
17	of that as well. So it would be a parallel
18	change in both documents.
19	Then are we ready to vote, then?
20	This is a recommendation to NIOSH. All in
21	favor, say aye.
22	(Chorus of ayes.)

1 CHAIRMAN ZIEMER: Proposed, no. 2 (No response.) CHAIRMAN ZIEMER: Abstentions? 3 4 (No response.) 5 CHAIRMAN ZIEMER: Ayes above the 6 nos. Okay. Now we are ready to do the Work 7 Group activities. There are two items in 8 there that perhaps we want to highlight first. 9 10 And that deals with security issues updates on Mound and Pinellas. Perhaps we 11 should do those two first. 12 Okay? 13 Well, we had the general Mound review, but what about security update 14 15 Mound? Do you have comments on that? 16 MR. KATZ: Let me just give some context for this. Dr. Melius at the last 17 Board meeting asked that we have regular 18 19 updates for these sites where there are sort of very special security concerns just to know 20 that things are proceeding well or if they are 21

not, what the issues are and whether we have

come to a point in any of these sites where we have very substantial difficulties in moving forward because of security matters, classified information, and so on.

So I have asked the two work group chairs who are dealing with these issues right now just to give an update as to how things are proceeding. Brad is indicating three. And that is fine. Any other work group that has these issues, certainly this is something that I think is in the interest of the Board to keep abreast of any issues that are arising here.

Thank you.

MEMBER BEACH: So, as far as Mound is concerned, we have not experienced any significant delays in reports, White Papers. I would say there is about a three to four-week lag time in our White Papers once we give them to DOE. So, in reality, we haven't had any problems.

I also did a report on the secure

NEAL R. GROSS

meeting that was set up for us. That was handled very well. So at this time Mound has not experienced any real issues with this security issues.

CHAIRMAN ZIEMER: And then, Phil, let's talk about Pinellas. And you can also talk about any other related matters for that site. We will consider that the Work Group report.

MEMBER SCHOFIELD: Okay. As far as the security issues, many of those issues were taken off the table when we met with DOE in Germantown, things that were of concern that they have basically opened the book to just about everything except for a few minor issues that we will have to work with. Otherwise they gave us the go-ahead to proceed.

Technical Right now the Document is with DOE for a review of the As soon as that comes back, we revisions. will schedule a work group meeting. I might well go ahead and hit INLand Idaho as

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

National Lab on the -- there is a matrix on that being worked on right now.

We are also going to combine Argonne National Labs West with INL into one review because they share common buildings, common sites. They just were so entwined you can't separate one from the other with the blessings of the Board.

CHAIRMAN ZIEMER: Jim?

MEMBER MELIUS: Can I ask? Yes. We at our Work Group meeting on Idaho -- I mean, frankly, the NIOSH staff seemed quite unprepared to deal with the SC&A comments. Has there been progress on that that you are aware of, Phil?

MEMBER SCHOFIELD: They are supposed to have a matrix ready for us on just the INL section of it, just in relation to INL without any of the Argonne National Lab West -- they haven't started on that is my understanding.

MEMBER MELIUS: When are they going

NEAL R. GROSS

1	to have it ready, I guess? Do you know? Have
2	you heard?
3	MEMBER SCHOFIELD: I have heard no
4	time frame yet.
5	MEMBER MELIUS: Okay.
6	CHAIRMAN ZIEMER: You are asking
7	about Argonne West or INEL?
8	MEMBER MELIUS: INL.
9	CHAIRMAN ZIEMER: Okay. Or it's
10	now INL. I am used to INEL. Okay.
11	Brad, did you have additional
12	comments also on the security matters?
13	MEMBER CLAWSON: Mine is a little
14	bit different because Mound and Pinellas are
15	actually gone, but I am dealing with an active
16	facility right now that has many security
17	issues.
18	Since the implementation of the
19	Board's procedure for retrieving documents and
20	so forth like that, we got off to a little bit
21	of a rough start. But it looks like it is
22	starting to work forward and going through

there.

It did please me to hear that Glenn had spoken the other day and his support to be able to help us get in there because in our case, there are some real national security issues and so forth, which we have been working on and we are preparing to go down and interview some claimants.

And we are also working on a tour down there in late August, early September, some time frame. But we are seeing some delays in kind of a miscommunication of some sorts, but overall it is working fairly good.

We are more having a hard time with the site itself, retrieving information.

CHAIRMAN ZIEMER: The tour that you refer to is for the Work Group itself? Is that?

MEMBER CLAWSON: Yes, it is. It is for the Work Group. And so it is closed to them because of a Q clearance that we have to be able to have and so forth.

NEAL R. GROSS

1	CHAIRMAN ZIEMER: Okay. We can
2	proceed.
3	MR. KATZ: Just to clarify, this is
4	Pantex that Brad is speaking for. I know all
5	of us here recognize that.
6	MEMBER CLAWSON: I appreciate that.
7	CHAIRMAN ZIEMER: Okay. Phil, do
8	you have an additional comment?
9	MEMBER SCHOFIELD: Actually, this
10	is more of a question. I was wondering if
11	Larry Elliott could give us any idea when
12	OTIB-0066 how they are going to use it and
13	how it would be applied, if they have any idea
14	when this is going to be ready.
15	CHAIRMAN ZIEMER: OTIB-0066, which
16	is? Remind us.
17	MEMBER SCHOFIELD: Is on the
18	tritium issues.
19	CHAIRMAN ZIEMER: On the tritium.
20	MR. ELLIOTT: OTIB-0066 is in
21	place. The issue, the question I think, Phil,
22	goes to how OTIB-0066 is referenced and

1	applied for a certain site, like Pinellas,
2	Pantex, or Mound. And we see that being
3	different in those different facility
4	situations.
5	So the Site Profile is going to
6	have to speak to how OTIB-0066 is employed at
7	that site. I don't know where that is at. I
8	don't have that right now for Mound or
9	Pinellas or Pantex. I think we are close.
10	There are discussions going on in
11	each of those work groups. I think you have
12	heard for Mound what the plan is, but I don't
13	believe the Site Profile has been fully
14	changed to reflect that yet.
15	MEMBER SCHOFIELD: Okay. Thank
16	you.
17	CHAIRMAN ZIEMER: Thank you. Okay.
18	Let's proceed through the other work groups
19	or at least get underway here for a few
20	minutes.
21	MR. KATZ: Okay. So Blockson we

are going to address later, right? Correct?

1	Then we have Chapman Valve. Dr. Poston?
2	MEMBER POSTON: We attempted to
3	schedule a telephone conference to try to wrap
4	up Chapman Valve and were unsuccessful. So we
5	will try again after this meeting. The summer
6	turns out to be very busy for a lot of folks.
7	And we were unable to schedule it.
8	MR. KATZ: And DOE Security; that's
9	Brad, but, really, we have gone forward on
10	that. That's really maybe
11	CHAIRMAN ZIEMER: I believe that
12	Work Group has finished the task, which was
13	the task of developing and recommending the
14	document. And that is basically completed.
15	MEMBER CLAWSON: Yes, it is
16	completed. But if you remember, in Amarillo,
17	you kept us together if security issues arose.
18	CHAIRMAN ZIEMER: Right. And,
19	actually, at some point if this becomes sort
20	of a standing group with a broader mission, we
21	may have to make that a subcommittee.

NEAL R. GROSS

Right.

MEMBER CLAWSON:

1 CHAIRMAN ZIEMER: But at least the 2 actual work that was originally charged to it was completed. 3 4 MEMBER CLAWSON: Yes. Ιt was completed, and they are implemented. 5 6 MR. KATZ: Right, yes. For the record, the documents were finalized. 7 have some comments from Dr. Melius about the 8 final documents, which I will circulate to the 9 I mean, they're 10 Board after this meeting. It would be minor changes. And they 11 relate to an issue that was raised on the 12 13 first day of this Board meeting. So those are in place. And I also 14 15 have from all of the Board members 16 certification that they're ready to comply with it, educated, and ready. And I have the 17 same from the SC&A organization. So we are 18 19 really all set. I will be sending a letter to the 20 Department of Energy just to document that for 21 their sake, for their security plan.

1 are in good shape there. 2 Then we have Fernald. And that is Mr. Clawson? 3 Fernald, 4 MEMBER CLAWSON: Yes, we've had three work group meetings so far. 5 6 We have got six outstanding issues being discussed at this time. 7 Three of the issues were being 8 addressed by SC&A, which has issued a White 9 10 They are in process right now of going to DOE and being cleared and then will be 11 submitted to NIOSH. NIOSH had three other 12 13 issues that they were looking into. And we are waiting for a report to come back from 14 15 that. 16 After we have had, both sides have had, time to review and digest what each side 17 is going to do, what they are discussing 18 19 about, then we are going to schedule a work group at that time. 20 MR. KATZ: Hanford, Dr. Melius? 21

NEAL R. GROSS

MEMBER MELIUS: Hanford, there has

been no activity. I believe I shared with the Work Group, I'm not sure with the Board NIOSH has reevaluated their approach on Hanford.

And at our October meeting, I think -- that is still on schedule -- they will be presenting essentially an expansion of the current SEC to cover more groups and more people. They will have a full explanation from the time right now to do that and a new Evaluation Report to justify that. I think it is coming in as 83.14.

MR. ELLIOTT: Yes, sir.

MEMBER MELIUS: Yes, and do that, which will cover a much longer time period. And so they are busy doing that. Arjun and I have some sort of technical calls and sort of administrative calls to get caught up on that, but we will all, the whole Board will, be able to see that in October, be presented to us. And hopefully we will have it a little bit before then. So there may be some need for the Work Group to meet and discuss it before

NEAL R. GROSS

the October meeting, but that somewhat depends 1 2 on the timing of this, of NIOSH. Meanwhile, we have worked with 3 Arjun to sort of adjust the matrix and our 4 plan for follow-up to take into account this 5 change by NIOSH. 6 7 MR. KATZ: Thank you. And then next we have -- we have covered INL, Phil has 8 covered that -- Linde, Dr. Roessler? 9 10 MEMBER ROESSLER: The Linde Work Group has been reconstituted. And the Chair, 11 Josie Beach, Mike Gibson, and Jim Lockey are 12 13 on it. We have scheduled a meeting for airport, Cincinnati September 2nd at the 14 15 Airport, Marriott starting at 9:30. And I had 16 hoped that the Work Group will expect to be there pretty much for a full day. 17 The focus of the meeting will be 18 19 the Linde SEC petition 107 covering 20

residual period, which is January 1st, 1954 to July 31st, 2006.

The meeting will include the OCAS

NEAL R. GROSS

21

presenting their petition evaluation and the petitioner presenting her petition since this petition has not been presented to the full Board.

[Identifying information redacted] is the petitioner. And I understand she will be at the meeting. Also, SC&A will present its review of the petition, which was completed in June of 2009. And OCAS will have the opportunity to respond to the SC&A review.

Thank you. MR. KATZ: And let me iust add little bit to that, which а [Identifying information redacted], the petitioner, had sent a letter to the Board concerning Linde. She had submitted petition for an interim period just prior to the period that is being covered by this petition that qualified.

And that relates to the review that was done by SC&A of the original Site Profile and the discussions that then underwent regarding that Site Profile.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

As part of reviewing the SEC petition that qualified, SC&A also looks over -- I mean, it's just part and parcel of that -- looked over the changes that were discussed for the Site Profile and then the new Site Profile that has been issued since to see what transpired in terms of implementing the sort of changes that were discussed for the Site Profile.

So I have asked SC&A prior to this Board meeting. She had wanted the Board to consider having the new Site Profile reviewed.

And I understood that SC&A had sort of done a considerable amount of work in looking at the new Site Profile in relation to this SEC petition.

So I asked them to just sort of fill in the holes in terms of addressing the changes that were made and how they were followed up on, which I think they have, they have undertaken and is underway.

As I understood from SC&A, it is a

NEAL R. GROSS

1	very small amount of additional work to
2	provide a memorandum to cover whatever wasn't
3	quite covered in the petition review document
4	itself. So they will be providing that.
5	And I would just ask that, although
6	this Board, I mean, the Working Group, is
7	taking up the petition, that they could follow
8	up on whatever issues might arise related to
9	the Site Profile, the new version of the Site
10	Profile in implementing those changes. So I
11	would just ask that for the Board to consider.
12	CHAIRMAN ZIEMER: Well, the tasking
13	has been done already. And I don't think any
14	formal action is needed at this time.
15	MR. KATZ: No. Just that the
16	Working Group could consider those
17	CHAIRMAN ZIEMER: Oh, the working
18	group.
19	MR. KATZ: elements as well, not
20	
21	CHAIRMAN ZIEMER: Yes, yes.
22	MR. KATZ: strictly the SEC

1	petition.
2	CHAIRMAN ZIEMER: The working group
3	I guess is have we named that an SEC?
4	MEMBER ROESSLER: I think you did,
5	yes, once the petition qualified.
6	CHAIRMAN ZIEMER: Yes, right. So
7	the issue is that of expanding the scope of
8	the Work Group to include this. Well, I am
9	not going to say it is necessarily minor, but
10	the Site Profile revisions.
11	Is there any objection on the part
12	of the Board members to expanding their charge
13	to over this?
14	(No response.)
15	CHAIRMAN ZIEMER: I see no
16	objections. And we will consider that their
17	charge is amended suitably to extend as
18	needed.
19	MR. KATZ: Thank you. So Los
20	Alamos National Lab, Mr. Griffon?
21	MEMBER GRIFFON: Yes. We haven't
22	had a meeting since the last Board meeting,

1 but I think we are getting close. There is 2 activity. I know SC&A was recently out to LANL doing document review 3 more and interviews, I believe. 4 I would hope before the next 5 So 6 full Board meeting we will have a work group 7 meeting but no update other than that. We have Mound MR. KATZ: Okay. 8

MR. KATZ: Okay. We have Mound already. Nevada Test Site, Mr. Presley?

MEMBER PRESLEY: NTS Working Group has not had a meeting since the last meeting. However, we have two outstanding issues. Those issues are being worked between HHS and SC&A.

Hopefully the outcome will become worked out before our next meeting and we can have a Working Group meeting to discuss the final outcome of the deliberation and move forward with the NTS Site Profile and the other document -- I am having a senior moment -- Technical Basis Document and the SEC.

MR. KATZ: Thank you.

NEAL R. GROSS

9

10

11

12

13

14

15

16

17

18

19

20

21

Rocky Flats, Mr. Griffon?

MEMBER GRIFFON: Rocky Flats. Yes, we did, as you sort of got briefed on this on the last two days, actually, but we did have a Work Group meeting on the 20th, I believe, just before this meeting, to discuss the -- it is still the one issue: implementation of the Class and the question of the University of Colorado/Ruttenber database and whether that has any implications on how the Department of will Labor implement the Class the Secretary proposed it.

I know there are requests for SC&A to sort of review this report that NIOSH put out, but Labor has just received this report. So what I think is the best path forward here would be to allow the Department of Labor some time to consider this report.

I spoke with Jeff yesterday, Jeff Kotsch from Labor. And, you know, he says they do have the report, but, really, they need a little more time to consider it and

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

whether it would impact their implementation 1 2 of the Class. And then after that, I think we 3 would consider tasking SC&A if needed. 4 think we want to get a read on DOL before we 5 6 move on this any further. And I don't know, Jeff, if you have 7 anything to add to that. 8 MR. KOTSCH: No, Mark. I mean, we 9 10 will. We just got it when you got In fact, I haven't even been in the received. 11 office in the last few weeks, but we will take 12 a look at it. 13 Also talked Larry about 14 we to the Ruttenber database 15 getting a copy of 16 because we haven't seen that yet either. So we will review those things and 17 Ι respond. 18 19 MEMBER GRIFFON: I mean, I will stay in close touch with all of the parties. 20 I think certainly we would hope that the 21

Department of Labor can get us a fairly quick

answer on this, on where it would stand.

And then, you know, we will deal with that afterwards and whether we need to ask SC&A to review the report. But first we want to hear back from Labor.

Larry wants to add.

MR. ELLIOTT: Yes. The database from the Ruttenbers is going to be placed on our secure data network and shared with DOL before the week is out.

And I have offered our technical team to Jeff to give them an interpretation and a navigational overview of the dataset because it is not straightforward and not self-explanatory. So we will help them with that.

If I could, I would like to make a couple of comments here because I certainly appreciate those folks during public comment who have pointed out that where we at NIOSH -- as we are scientists, we are not effective communicators in all respects.

NEAL R. GROSS

And so I want to point out that we haven't done as good a job as I wanted to on communicating about this Ruttenber study. And I would like to expand on what I said Monday just for the record and to be clear.

The analysis that is outlined in the report has confirmed that our original understanding that Dr. Ruttenber and then his wife Margaret Ruttenber gave us was that the data used by the Ruttenbers came from the Rocky Flats radiation protection group, same data that was being incorporated and developed into the NDRP. So it is the same data source. Both the Ruttenber and the NDRP studies start with the same dosimetry data source.

While the Ruttenber team clearly expressed to Rocky Flats personnel and the NDRP that they would like to use the NDRP, it wasn't ready at the time that they conducted their study.

And so the data that they had been given required them to make some assessments

NEAL R. GROSS

of whether or not neutron exposure occurred for certain types of job categories that weren't reported to them in the NDRP data that they had received.

They, therefore, felt that any member of a job classification or category that might have had opportunity to enter one of the identified buildings where plutonium and neutron exposures could have existed should be given an imputed dose, an assigned dose, a dose that is estimated to potential for that kind been а activity for that kind of job category. all people in that job category would have been assigned that dose.

So when the Ruttenbers assigned these doses, the NDRP relied primarily on dosimetry records constructed in detail as individual work histories and time lines. And he assigned those doses to workers if there was evidence of a neutron exposure in a building they went into.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

no difference in There is the neutron identified buildings in the NDRP from the buildings in the Ruttenber neutron dataset. They are the same. The buildings that have been identified as neutron exposure buildings are the same.

It is important to remember, I think, that NIOSH's responsibility here is to the claimants. And so when we developed this evaluation, we talked with the team about how they were going to evaluate the two datasets.

You know, our responsibility is to the claimants. So we focused on the 100 current claims that we had in our system. And for Rocky Flats workers who were not included in the NDRP prior to 1967 but for whom the Ruttenber data imputed a neutron dose, there were of these 100 claims, 50 individuals that were already included in the SEC Class. There were 22 that had non-SEC cancers and nine had less than 250 days of employment in the SEC period.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Four had dose reconstructions that had a PoC of greater than 50 percent. And three individual claims were closed because either the employee died or the survivors died, which is just terrible in my opinion. That is where we fail these folks dramatically.

And one had a non-SEC cancer but was compensated for beryllium exposure. So for the total of 89 of the 100 claimants with imputed neutron doses in the Ruttenber database, this data can have no impact on the compensation decision.

In addition, the imputed annual neutron doses in the Ruttenber database are less than 100 millirem for each year in the SEC period for 10 of the remaining 11 individuals.

A detailed review of these claimants' dosimetry files was conducted. And there was nothing that suggests that neutron exposure occurred for them prior to 1967.

NEAL R. GROSS

That is, there were no neutron dosimetry results, no incident reports from a plutonium building, no plutonium bioassay results, or any other evidence indicative of neutron exposure potential.

There is one claimant with an annual neutron dose of greater than 100 millirem in the Ruttenber database but not in the NDRP. And there is no evidence of neutron exposure potential for this individual in his dosimetry files.

So I quess, in summary, NIOSH in our evaluation has determined that the impact of using the Ruttenber database, in addition to the NDRP for determining eligibility in this Special Exposure Cohort Class, decision that DOL needs to make. We have tried to give them an understanding based upon claims that we have how this Ruttenber database would affect that population.

So if we have missed the mark, I apologize for the poor communication of this,

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

but I sensed enough irritation about it, enough frustration about it from public comment I felt I wanted to clarify the record.

MEMBER GRIFFON: Let me just add, I think you got pretty far down into the weeds there. And I am not going to redo our work group conversation because we got quite into these details and how the 100 cases were considered.

This is all part of this report, which is available for everybody. It is on the website, on the O: drive, also. You know, I think now let's let DOL look at it and consider it.

The one thing that I would ask -- and it came out of the Work Group -- is that the analysis of those 100 cases would be added to the O: drive.

And I haven't seen. I looked right before the meeting to see if that was posted, and I don't think it has been put up there yet.

NEAL R. GROSS

So if NIOSH could do that for us and for DOL, I think that might be helpful, too, to understand all of those details you just went through and see that but anyway.

CHAIRMAN ZIEMER: Dr. Melius?

MEMBER MELIUS: Again, without trying to belabor the situation but I'll agree with one thing, Larry, that this was a poorly communicated report. I found it to be very confusing, very poorly written.

And I would object. I think the duty of NIOSH and certainly the duty of the Board is to more than just the 100 claimants. It is to a whole class of potential claimants and whether in reviewing and defining a Class definition we made the proper designation and that the Ruttenber data offered a new source of data.

So I think we have an obligation to look into this more than just to do with the 100, what happened to 100, claimants, whether they are a convenient sample that can be used.

NEAL R. GROSS

And I can understand why they were looked into.

I am also comfortable with DOL, I think needs to take a look at this given where we are in implementing this Class. And I think we need to be appropriately careful and prudent in how we approach this now given what has gone on. So I think feedback from DOL would be welcome. And then let's see where we need to go with this.

CHAIRMAN ZIEMER: Well, indeed, the issue has really focused on the implementation of a Class which has already been approved. And if, in fact, DOL after looking at this determines that there should be some modification, that will impact on what we do next.

So it is very appropriate to let DOL take a look at this first. And then we can determine a course after we see what comes out of that.

So thank you very much. Let's go

NEAL R. GROSS

1	ahead.
2	MR. KATZ: Santa Susana, Mr.
3	Gibson?
4	MEMBER GIBSON: We met April 17th
5	in Cincinnati. We went over the matrix and
6	the concerns that SC&A had. Those concerns
7	are in NIOSH's hands right now. They made no
8	response to them. We're awaiting that.
9	Also since last meeting, I have
LO	become aware of some information that is out
L1	there that I don't think SC&A has reviewed yet
L2	that I haven't been able to share this with
L3	the rest of the Work Group.
L4	So I am not comfortable with asking
L5	SC&A to do that now, until I talk to the rest
L6	of the Work Group. But, just for your
L7	information, I think there may be some
L8	additional tasking we want to do for SC&A to
L9	do some additional review.
20	MR. KATZ: Thank you, Mike.
21	Savannah River site, Mr. Griffon?
22	MEMBER GRIFFON: Yes, pretty much

the same update as for Los Alamos. We close, but we haven't had a meeting yet. And SC&A has also been down there. Joe's group gets around.

Again, I think early fall we are expecting to have a work group start up down in Savannah and maybe in the area, actually. I am not sure about that because we might coincide it with data collection activities. So it will either be in our normal spot, Cincinnati, or Savannah. And that is it.

SEC issues, Dr. Melius? MEMBER MELIUS: The SEC Issues Work by conference call, I believe, Group met stealing or beating John Poston to the one open time we had. Sorry, John. We all had scheduling problems between health physics and other vacation schedules and so forth.

MR. KATZ:

Anyway, met, reviewed we two One was the Dow SEC petition, which things. was mainly trying to update and make sure where stood with a variety of issues we

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

related to that.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

We do need to task SC&A with one more review related to that. It is not a large task, but the Appendix, I think it's Appendix C, but Ι may be wrong, to TBD-6000, which covers Dow and needs to be reviewed by SC&A, they haven't reviewed it in relationship to the SEC because I wasn't available at the time they did their And there are a few other technical review. informational things.

I think if SC&A proceeds correctly,

I think we will try to do another Work Group

meeting before the October meeting and

hopefully can bring some closure to that SEC

evaluation review.

The other potential problem there is that the residual covered period is being under evaluation also. And there may be some changes to that and being forwarded from NIOSH. The timing on that is sort of out of our hands, but we may want to proceed anyway,

NEAL R. GROSS

1	but that could complicate the timing a little
2	bit.
3	The second issue we looked at was
4	we had the discussion on the 250-day issue
5	involving the Metallurgical Laboratory,
6	Chicago and I think, again, more of a
7	technical discussion about how to approach
8	that problem. And I think it was a good
9	discussion. We will need to do follow-up.
10	So I think probably at the same
11	time we do Dow, we will probably have a
12	meeting of the Work Group to also discuss the
13	250-day issue.
14	MR. KATZ: Any questions?
15	(No response.)
16	MR. KATZ: Thanks, Dr. Melius.
17	And, just for clarity here, SC&A was tasked at
18	the Work Group meeting to take on Appendix C.
19	Okay. So then we have TBD-6000,
20	6001.
21	CHAIRMAN ZIEMER: This Work Group
22	has been focusing mainly on the Appendix B,

which is the General Steel Industries issue.

And at the last Board meeting, we tasked SC&A

to look at the SEC Petition Evaluation Report.

SC&A has completed that. And that report has been sent to DOE for clearance. It has not yet come to the Work Group. I think it went to DOE last week, late last week.

And we expect that to be out to the Work Group perhaps in a week or two. And once we have that report from SC&A, we will be ready to schedule our next Work Group meeting.

In relation to General Steel in the meantime, there have been some other activities. SC&A staff people have also done some phone interviews with some of the General Steel workers to clarify some of the issues that have arisen.

We have had a fair amount of input from both the petitioner and the site expert. So that there is a fair amount of additional information for the Work Group to look at as well.

NEAL R. GROSS

1	So as soon as we get the SC&A
2	report, we will be ready to schedule a meeting
3	within the next four to six weeks.
4	MR. KATZ: Thank you, Dr. Ziemer.
5	Surrogate Data, Dr. Melius?
6	MEMBER MELIUS: Nothing new to
7	report. We will be planning to try to hold a
8	Work Group meeting between now and the October
9	meeting on that.
10	We took our own time. The time
11	available for that was also like that 3:00
12	o'clock last Friday.
13	MR. KATZ: I see a very busy fall
14	ahead of us for work groups, which is great,
15	actually.
16	And, Mr. Gibson, Worker Outreach?
17	MEMBER GIBSON: Yes. We met in
18	Cincinnati on June the 16th. And we have
19	another meeting scheduled August the 12th in
20	Cincinnati.
21	We tried to find how we are going
22	to assess the worker outreach efforts. We put

together some draft language, and we are still working with that. But today there are a couple of issues.

Number one, we would like to

present to the Board a draft mission statement to see if the Board would concur for us to adopt that. The mission statement is, the mission of the Advisory Board on Radiation and Worker Health's Worker Outreach Work Group is to monitor and assess the effectiveness of NIOSH and other sources of assistance for potential EEOICPA claimants and assure this information is available to as many current and former workers of the U.S. weapons complex as possible.

CHAIRMAN ZIEMER: I interpret that as a motion for approval of the Board for sort of the charge to the Work Group.

MEMBER GIBSON: Yes.

CHAIRMAN ZIEMER: And if there's a second, we will discuss that.

MEMBER BEACH: I will second that.

NEAL R. GROSS

CHAIRMAN ZIEMER: And there is a second. Before we actually discuss the motion, let me point out that when the Worker Outreach Work Group was proposed -- and I believe, Mike, you actually proposed it originally -- both Mike and the chair and maybe the full Board, we weren't completely clear as to what exactly the Work Group should do except sort of an intuitive feeling that they needed to take a look at how outreach is being done.

A lot of that is done by Labor, but NIOSH certainly has activities and works with Labor in these outreach activities. And so basically the Work Group had the opportunity to define their task.

They have deliberated on this over the past number of months and determined that this would be the kind of framework in which they could move forward.

So I think it is in that context that Mike and the Work Group have proposed

NEAL R. GROSS

this as sort of their official charge. And I would like to ask if any of the Board members -- do you need to hear the words again?

Because we haven't seen this in writing.

So why don't you read it once again for us just so we have it clear in our minds what the charge would be?

MEMBER GIBSON: The mission of the Radiation Advisory and Worker Board on Health's Worker Outreach Work Group monitor and assess the effectiveness of NIOSH and other sources of assistance for potential EEOICPA claimants and assure this information is available to as many current and former workers of the U.S. complex weapons possible.

CHAIRMAN ZIEMER: Okay. Thank you.

The key points here I think are monitor and assess. And as the Work Group moves forward if we approve this, they would have to determine, actually, how to do the assessing.

And that would be their next step and then

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

the issue of sort of making sure that the word gets out there. And that has some implications itself in terms of how that would be done.

MEMBER GIBSON: And we do have some draft language that we are still commenting on that we think is leading us down the road on what we are going to assess and how to assess it.

an overall sort of charge with the understanding that details on how to actually do this, the group would work out. We would assume that, Mike, you would report back to us as you make progress and get input from the Board.

I think this is a very important Work Group in terms of overall impact on the program. And so it would be important to get feedback from the Board itself.

When counsel whispers in someone's ear, I always pause.

NEAL R. GROSS

MR. KATZ: No. It's okay. has just advised me about a concern because it's vaque language. I think in the language that it was NIOSH and other sources of And the concern was that if DOL assistance. is considered another source, that DOL really outside of the scope of the charter for the Board to be evaluating DOL actively.

CHAIRMAN ZIEMER: Well, let me just comment that we are certainly not going to be formally evaluating DOL. I think Mike would understand this. And we want to make clear that if there are things that we, NIOSH, can do of and some these might be in conjunction, Ι guess, with DOL activities because we are often there.

So I think we want to make it clear that we are not making recommendations to DOL. It would be surprising to me if in the process of the activities, that one might note something in terms of how things -- I mean, it happens in our regular meetings. We hear from

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

claimants. We hear from public comments issues that are often DOL-related issues. But they get sort of merged together.

So we are not going to try to control or recommend to DOL. It would be surprising to me, though, that if the activities were completely divorced in terms of the fact that we do try to work together with DOL on this.

So I think, for Ms. Howell, we will certainly try to steer clear and stay in our own boundaries. And I don't think we want to say that the other entities as code words for DOL or anything like that.

Well, enough said on that. Maybe others have comments. I see a number. Brad has a comment, Dr. Lockey.

MEMBER GIBSON: Mr. Chairman, could I respond? We totally understand that our duties are to advise NIOSH and that you are exactly right, Paul. The reason the other sources were put in there is because many of

NEAL R. GROSS

the meetings are initiated by DOL. And NIOSH attends those meetings. And so, as a work group, we would like to be there, too.

We have been there in the past. And there are going to be potential comments on how NIOSH was or was not effective in those meetings. And if there is something that we see concerning DOL, if we bring it to the Board, we have made comments to other agencies in the past about other issues. And that may happen in the future.

But we understand that we are just to assess the NIOSH program and its outreach.

CHAIRMAN ZIEMER: Brad?

MEMBER CLAWSON: And I understand what Emily has put forth, but the one thing I didn't want us to meet. Being able to have been asked to go to a couple of DOL meetings at one of the sites that I am in the Work Group for, there was some very interesting and some very important information that came out in there.

This is what I kind of see as the worker outreach process is doing to us to make sure that this information that is talked about in a public setting or so forth like that isn't lost, that we're taking acknowledgment.

And also, too, from the people that

And also, too, from the people that were there, they appreciated knowing that the Advisory Board did have an interest in what was being said. And I don't want to ever be able to lose that.

I understand we can't tell DOL or anything else like that, but there is some very, very good information that comes out.

CHAIRMAN ZIEMER: Wanda?

MEMBER MUNN: If there is going to be heat about the other sources comment, you need to direct it at me because I was highly instrumental in suggesting that we include that language.

The Department of Labor was actually the last of the sources that I was

NEAL R. GROSS

considering. We know we have no responsibility at all toward what Labor, the Department of Labor, does or does not do.

On the other hand, professional organizations, organized labor organizations, and by this point even attorneys are involved throughout the entire country in attempting to provide information to claimants, both positive and negative information.

Τf we do not take into consideration the fact that -- if we are going assess how claimants are getting information and do not we even pay attention to other sources, then it appears to me that we're failing what I believe most of this work group interpreted was our charge.

CHAIRMAN ZIEMER: Jim?

MEMBER LOCKEY: When I listen to the language, when I hear the word assess, that means it is an active process that means resources being committed to a working group.

Are you saying that the working group itself

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	is going to go out and assess or have
2	resources to do the assessment or are you
3	going to be making recommendations as to how
4	NIOSH should assess it?
5	MEMBER GIBSON: We have in the past
6	and we continue to physically go to meetings
7	and assess the process as it goes forward.
8	NIOSH, they have changed the
9	database on how they used to track worker
10	comments into a different type of database.
11	And that is close to going online and being
12	shared with us.
13	So there will be some review of
14	stuff like that, too, you know, just directly
15	with NIOSH. So it is going to be a
16	combination of both.
17	MEMBER LOCKEY: So active working
18	group assessment, attending meetings, as well
19	as making recommendations as to how NIOSH
20	should assess the program?
21	MEMBER GIBSON: Yes.
22	MEMBER LOCKEY: Okay.

NEAL R. GROSS

CHAIRMAN ZIEMER: Ted?

MR. KATZ: I don't want to be a stickler about language. It is just for the charge of the Work Group. So I am not suggesting it has to change, but monitor normally implies an ongoing activity.

And just we need to keep in mind that this is a working group. And as long as it is going to be a working group, it has a sort of finite charge, a beginning and an end to it. If it were to become a more monitoring type of function, it would need to be a subcommittee.

CHAIRMAN ZIEMER: I fully agree.

And this is one of those areas. And it is not focused on a specific site and might very well morph or merge or move into that mode.

I think once we have their charge and a better delineation of what they are going to do, we will be in a position to answer that. I still consider it somewhat ad hoc until we reach that point. I very well

NEAL R. GROSS

would expect it might become a subcommittee.

MEMBER GIBSON: And the second issue I told you that we were going to discuss today is we have not formally voted as a work group to make a motion to the Board.

But the thing I think we have consensus on and I wanted to throw out for the Board's consideration is changing us. We have presented a draft basic task to you that we want to go after, but we think that task is going to be an ongoing thing. So we wanted to throw out for short discussion or whatever here today about modifying this work group or changing the status to a subcommittee.

CHAIRMAN ZIEMER: Well, that is the point, then. And I would suggest that for today, we simply vote on this new -- what do we call it? -- charter, as it were.

And once you come back with the details on monitoring and assessing, we get a kind of a full feel for the scope, it might be an appropriate time to take the next step,

NEAL R. GROSS

then, if that is agreeable.

Jim?

MEMBER LOCKEY: I would feel comfortable if we could see the statement and the objectives, what you are proposing, going forward really outlines -- so that gives us an idea of what you all are committing to.

It sounds like it needs to go to a subcommittee, but perhaps having the objectives in the outline under the statement also would be very helpful so we can get our arms around this.

MEMBER GIBSON: And that is. We do have that in draft form. We are still commenting on it as a work group. And NIOSH has got some comments in on it. We just didn't have it ready for today.

CHAIRMAN ZIEMER: I think we are still discussing the original motion. And then those other details would come perhaps at the next meeting, at which point we could take the follow-up action.

NEAL R. GROSS

1	Let me ask you if the Board is
2	ready to vote on this motion. This is I will
3	call it the monitor and assess motion. How is
4	that? All in favor, aye?
5	(Chorus of ayes.)
6	CHAIRMAN ZIEMER: Opposed, no?
7	(No response.)
8	CHAIRMAN ZIEMER: Abstentions?
9	(No response.)
10	CHAIRMAN ZIEMER: The motion
11	carries. Thank you very much. Thank you,
12	Mike.
13	MR. KATZ: I think that is it.
14	CHAIRMAN ZIEMER: That is it.
15	MEMBER CLAWSON: I just covered
16	Pantex.
17	CHAIRMAN ZIEMER: Okay. We have a
18	little add-on. And then we are going to take
19	our break. It is too bad we are not able to
20	do dose reconstruction selection, but we will
21	do that after the break.

Go ahead.

MEMBER CLAWSON: I just wanted to report on Pantex. We have had two site visits there. Like I said earlier, Pantex is different than what we have dealt with a lot because there are a lot of security issues. The Work Group is made up of a few cleared people so that we are getting access to this information and we will be able to see it.

SC&A submitted its report to NIOSH last December. They had to take and tweak it a little bit. And it was reissued in the April time frame. And we are waiting at this time for a response from NIOSH on the SC&A report.

After that happens, we are going to be able to schedule a work group meeting. But, like I said earlier, the first of August, early September time frame, the Work Group is going to go down or not work group but SC&A is going to go down and the members from the Work Group have the opportunity to go down. They are going to have some worker interviews and

NEAL R. GROSS

1	so forth like that.
2	And then once we get the report
3	back from NIOSH, which if we could get a time
4	frame, it would kind of help us towards a work
5	group scheduling. And we'll go from there.
6	CHAIRMAN ZIEMER: Thank you very
7	much.
8	Then let's take a break until
9	11:30. Then we are going to come back. We
10	need to do dose reconstruction case selection.
11	We need to take care of the Oak Ridge
12	Hospital Work Group. We need to complete some
13	work on Blockson. So we will have about an
14	hour to finish that up.
15	(Whereupon, the above-entitled
16	matter went off the record at
17	11:11 a.m. and resumed at 11:35
18	a.m.)
19	CHAIRMAN ZIEMER: We will now
20	reconvene our session. The next item on the
21	agenda, part of our Board working time, is the
l	

dose reconstruction case selection.

1	Mark is prepared to lead us through
2	there. Mark and I have conferred on this.
3	The suggestion is Mark will indicate the
4	cases. And we will do this page by page. He
5	has preselected some and will ask for
6	additional suggestions on each page. And we
7	will try to move through this more rapidly.
8	I told Mark if we take more than
9	one minute per selection, we are going to use
10	up our whole hour with this. So we want to be
11	fairly efficient.
12	So, Mark, you are working off the
13	copy that has them numbered in order starting
14	with we will just use the last three
15	digits, 201,
16	MEMBER GRIFFON: Yes, 201.
17	CHAIRMAN ZIEMER: so the
18	sequential copy, and move through that page by
19	page. Okay. Mark, it's yours.
20	MEMBER GRIFFON: Yes. And I'll
21	just say quickly I came up with like around 68
22	or 70 cases. These are kind of preselected.

1 We always know that we lose some on the next 2 step. So we are ultimately trying for 38. So I will go through my choices. 3 4 And then if you have any additions 5 subtractions or whatever, we will do it page by page. 6 7 MEMBER MUNN: Mark? MEMBER GRIFFON: 8 MEMBER MUNN: What criteria did you 9 10 Because I ended up just randomizing my selections and --11 MEMBER GRIFFON: I mean, basically 12 13 similar criteria that we have used in the I mean, I generally looked for cases 14 past. 15 under 50 but near 50, 45 to 50. This is 16 sorted on 30 to 60. So it is a little broader. 17 So the choices, I always look for 18 19 the site choices. If there was a unique site that I -- and I did this by memory. 20 I didn't really go back to our -- SC&A has a tracking 21 matrix for us of all of the sites we have 22

looked at and the numbers and all of that.

But I tried to look at if there looked like a unique site that we haven't seen before, that would be worth -- because that ends up being like the mini Site Profile Review situation. So I might have selected that.

MEMBER MUNN: So you pretty much used the same variance of criteria that was used before yours were, --

MEMBER GRIFFON: Pretty much, yes.

MEMBER MUNN: -- where they were --

MEMBER GRIFFON: And I figure we can fine-tune this on the Subcommittee. Once we get down to the final selection, we can look and say, you know, if we end up with a dozen Savannah Rivers and we look at our total numbers from before and we're getting too many Savannahs, we may want to drop some of those off or something like that. So this is like a first triage. So I went broader than we will end up.

NEAL R. GROSS

1	Okay. So on the first page, I have
2	205, 207, 208, 211, 212, 218, 220, 221, and
3	222. Any additions or ones that I mentioned
4	that you want to remove? We can look at those
5	now.
6	MEMBER CLAWSON: I had 207 or did
7	you say that one?
8	MEMBER GRIFFON: I said 207, yes.
9	MEMBER CLAWSON: Okay. How about
10	213?
11	MEMBER GRIFFON: I didn't have 213
12	because it is a yes, that is a possibility.
13	It is Iowa, but it is a non-SEC cancer,
14	correct? So I can add that, 213.
15	Any others to add or subtract?
16	(No response.)
17	MEMBER GRIFFON: Okay. Let me know
18	if I need to slow down on this, but we will
19	try to keep them moving.
20	MEMBER MUNN: I had marked 202,
21	Mark, just because liver is one of those that
22	doesn't come off a lot.

1	MEMBER GRIFFON: We looked at
2	Bethlehem Steel, and it is a site-wide model.
3	That is why I didn't
4	MEMBER MUNN: No problem.
5	MEMBER GRIFFON: Okay. Page 2, I
6	have 224 and 227. And that was it on that
7	page from me. Any additions or
8	MEMBER CLAWSON: I just had 247 was
9	all.
LO	MEMBER GRIFFON: Two forty-seven?
11	MEMBER CLAWSON: Yes, very bottom
L2	of the page.
L3	MEMBER GRIFFON: Well, we can
L4	consider that. I think we looked at Superior
L5	Steel. And it is a site-wide model again.
L6	MEMBER CLAWSON: Okay.
L7	MEMBER GRIFFON: So I would, yes.
L8	MEMBER CLAWSON: No problem.
L9	MEMBER GRIFFON: So we will leave
20	that off.
21	MEMBER MUNN: And I marked 246
22	primarily because of Albuquerque.

1	MEMBER GRIFFON: 246, Albuquerque
2	Operations Office. That is true. I don't
3	think we have looked at that. So that is
4	fine. Is that it?
5	Page 3, I don't have any. Most of
6	these are over 50 percent. That is part of
7	the reason I think I don't have any on this
8	page.
9	MEMBER MUNN: I marked 249.
10	MEMBER GRIFFON: I am sorry, Wanda.
11	I didn't hear.
12	MEMBER MUNN: I said I marked 249.
13	I thought that was one of those very near the
14	tipping point.
15	MEMBER GRIFFON: A lot of work
16	experience and very near. Okay. Yes.
17	MEMBER MUNN: Yes.
18	MEMBER GRIFFON: Two forty-nine.
19	We will add that on.
20	MEMBER CLAWSON: Two sixty-six is
21	one that I marked.
22	MEMBER GRIFFON: Okay.

1	MEMBER MUNN: Two sixty-six?
2	MEMBER GRIFFON: Two sixty-six.
3	MEMBER MUNN: Okay.
4	MEMBER GRIFFON: We will add that.
5	All right.
6	Next page is I have 275, 283, 284.
7	And 283-284 I picked for the very unique time
8	period that they worked and the fact that one
9	of them, actually, Paducah, 284, is a less
10	than one year and 51 percent on lung cancer,
11	which is kind of interesting to me.
12	So 275, 283, and 284 is all I have
13	on that page. Any others?
14	MEMBER CLAWSON: I had 285. I know
15	that it is compensated, but I was just
16	interested in all of the different sites. And
17	it was only 7.9 years.
18	MEMBER GRIFFON: Yes. We did have
19	several that had a bunch of Oak Ridge sites,
20	but I am willing to add it if other people
21	agree.
22	MEMBER CLAWSON: Just a suggestion.

MEMBER GRIFFON: All right. I
don't want to make Stu's work too big. The
idea is to narrow the list, but we can add
that one, 285.
Page 5, I have are we on page 5?
Yes. Page 5, I have nothing. A lot of these
are over 50, I think most of them.
MEMBER MUNN: I marked
MEMBER GRIFFON: Yes?
MEMBER MUNN: 297.
MEMBER GRIFFON: Two ninety-seven?
MEMBER MUNN: Two ninety-seven. As
I said, I was doing these fairly randomly, but
we haven't had many non-melanoma skin that we
have marked so far, have we?
MEMBER GRIFFON: No. I am willing
to add that one.
MEMBER CLAWSON: Mark, I had one
that was 292 that Iowa Ammunitions, but it was
non-compensated. But it was close. That's
why I marked it.

MEMBER GRIFFON:

22

Yes. And we just

1	added another Iowa one on. So I would say
2	they are going to be similar models there. I
3	would think one of those would be enough if
4	that is okay. I don't want to get too high
5	with the numbers here.
6	MEMBER CLAWSON: That's fine.
7	MEMBER GRIFFON: Page 6 I don't
8	have any on. Again, a lot of these were 50
9	percent. And I realized as I went through the
10	whole document that there were plenty in the
11	range that we wanted. So I tried to stay away
12	from a lot of the ones that were compensable.
13	MEMBER MUNN: Well, but some of
14	them
15	MEMBER GRIFFON: Does anybody have
16	any on page 6?
17	MEMBER GIBSON: Do we have any for
18	Santa Susana?
19	MEMBER GRIFFON: I'm sorry? Three
20	fourteen did I hear? Oh, yes. He worked a
21	long time. Yes.

MEMBER MUNN: It is those.

1	MEMBER GRIFFON: Yes, yes.
2	MEMBER MUNN: It is those extra
3	hours you get for extra shifts.
4	MEMBER GRIFFON: Ask him what diet
5	he's on, right, he or she?
6	MEMBER GIBSON: Mark?
7	MEMBER GRIFFON: Yes?
8	MEMBER GIBSON: Three nineteen.
9	Have we done many from Santa Susana?
10	MEMBER GRIFFON: I don't think so.
11	We can mark it down. It is a compensable
12	one, but I'm not sure we have done Santa
13	Susana.
14	MR. HINNEFELD: Excuse me, Mark.
15	Did you select 314?
16	MEMBER GRIFFON: No.
17	MEMBER ROESSLER: No.
18	MEMBER GRIFFON: We just pointed
19	out
20	MEMBER ROESSLER: I think that has
21	got to be a
22	MEMBER GRIFFON: Yes. So 319 is

1	the only one I added on that page.
2	Page 7, I have 342.
3	MEMBER MUNN: So did I.
4	MEMBER GRIFFON: And that is it.
5	MEMBER MUNN: I had 344.
6	MEMBER GRIFFON: Yes. I started to
7	have that. But then I saw .3 years worked,
8	and it wasn't so interesting to me anymore.
9	MEMBER MUNN: It's another one of
LO	those how do you get even that high with .3
L1	years worked.
L2	MEMBER GRIFFON: Yes. Okay. I can
L3	put that down, 344. Yes.
L4	MEMBER MUNN: I assume that's all
L5	assumed.
L6	MEMBER GRIFFON: Page 8. I had 347
L7	for the same reason as I stated before, that
L8	.2 years worked and the compensable lung
L9	cancer, 356 and 358.
20	MEMBER PRESLEY: Mark, I've got two
21	on there, 361 and 362. These are both
22	Bethlehem Steel.

1	MEMBER GRIFFON: But they are very
2	close, right? Is that right?
3	MEMBER PRESLEY: Yes.
4	MEMBER GRIFFON: Yes.
5	MEMBER PRESLEY: One of them is
6	49.44, and the other is 46.58. And they are
7	both almost 35. One is 37 years. One is 35
8	years.
9	MEMBER GRIFFON: Yes. I have those
10	as question marks. What if we pick 361
11	because they are the same model?
12	MEMBER PRESLEY: Yes, they are the
13	same model.
14	MEMBER GRIFFON: And one is very
15	close. You are right.
16	MEMBER PRESLEY: Okay.
17	MEMBER GRIFFON: Yes. Three
18	sixty-one we'll do. Okay.
19	Page 9, I have 369 and 377.
20	MEMBER PRESLEY: I have got 374.
21	It is a lot of years, and it's close, up at
22	Portsmouth.

1	MEMBER GRIFFON: Okay.
2	MEMBER PRESLEY: And it is in the
3	early years. And I have got one from Rocky
4	Flats that is 377.
5	MEMBER GRIFFON: I had that one,
6	yes.
7	MEMBER PRESLEY: Okay. I'm sorry.
8	MEMBER CLAWSON: I have 364. It's
9	compensated, but I just found it interesting,
10	all the different sites, 41 years worth of
11	work.
12	MEMBER MUNN: Yes. I marked that
13	one, too.
14	MEMBER GRIFFON: Okay. Three
15	sixty-four.
16	Page 10 is, I have, 380, 381, 390,
17	and 391.
18	MEMBER MUNN: Would you say those
19	again please, Mark?
20	MEMBER GRIFFON: Three eighty, 381,
21	390, and 391.
22	MEMBER CLAWSON: Mark, this is

1	probably the same model, but what I found
2	interesting was nine years work at Bethlehem
3	Steel. That's at 392.
4	MEMBER GRIFFON: Yes.
5	MEMBER CLAWSON: And it's at 49.57.
6	MEMBER GRIFFON: Yes. I mean, I
7	feel like it's the same. We just picked one
8	that was real close.
9	MEMBER CLAWSON: Okay. I didn't
10	remember if that was Bethlehem Steel or not.
11	MEMBER GRIFFON: Yes, it was
12	Bethlehem Steel. There's your round-off, too,
13	Paul.
14	Any more on page 10?
15	(No response.)
16	MEMBER GRIFFON: Page 11?
17	MEMBER PRESLEY: I've got 403.
18	MEMBER GRIFFON: Hold on. We are
19	going back to 392. We can look at this on the
20	next phase, but we might want to swap that out
21	with the other one, you know. Yes. Yes, 392
22	I will add on.

1	Next page I have 397, 398, 399, and
2	402.
3	MEMBER PRESLEY: How about 403?
4	It's a high number, 20 years. And I don't
5	think we have done a whole lot of General
6	Steel.
7	MEMBER GRIFFON: Well, I would say
8	let's not do 402 and then just do 403,
9	probably the same model.
10	MEMBER PRESLEY: Yes.
11	MEMBER CLAWSON: What about 404?
12	MEMBER GRIFFON: I think anyway.
13	MEMBER PRESLEY: All three of those
14	are
15	MEMBER MUNN: Could be the same
16	model.
17	MEMBER PRESLEY: The other one is
18	real close.
19	MEMBER GRIFFON: So, how about 403
20	and then 397, 398, 399? Is that right?
21	MEMBER CLAWSON: Mark, I liked 404.
22	It's low, but it's General Steel. But these

2	other guys, 33 years.
3	MEMBER GRIFFON: Again, I am
4	expecting it is the same model for all three.
5	MEMBER CLAWSON: Okay.
6	MEMBER GRIFFON: So I am not really
7	wedded to which one we pick, but I think we
8	should just stick with 403 if that is all
9	right.
10	MEMBER CLAWSON: That's fine. I
11	was just seeing the different cancer.
12	MEMBER GRIFFON: Page 12.
13	CHAIRMAN ZIEMER: Which did we
14	decide on?
15	MEMBER GRIFFON: Four-o-three.
16	Page 12 is 416, 421, 422, and 430.
17	And 421 I am not so wedded. I think I would
18	drop off 421, actually, because I picked that
19	for the reason you added the other one, Brad,
20	was the multiple sites.
21	MEMBER CLAWSON: Okay.
22	MEMBER GRIFFON: But I would drop
	NEAL D. ODOGO

are almost ten years more than any of these

1	it off now. So 416, 422, 430. That's what
2	I've got. And I believe U.S. Steel Company
3	National Tube Division is a site we haven't
4	done. So that is why I added that on. Yes.
5	It's one of those. It would be a mini Site
6	Profile review kind of thing. So 416, 422,
7	and 430.
8	Page 13 I have 439 because I
9	haven't seen that site before, 442. Four-
10	forty-three because I don't think we have done
11	DuPont either, DuPont Deepwater Works; 445;
12	446; 450; '51 and '52.
13	Four fifty I picked because this
14	person and this might be not a typo. He
15	worked 57 and a half years, he or she, so
16	could still be employed, started in '50.
17	MEMBER CLAWSON: The only one that
18	I had is 434 at the very top of the page. I
19	know it's a General Steel, but all other
20	ill-defined sites.
21	MEMBER MUNN: Yes. We just had

22

another one of --

1	MEMBER GRIFFON: Yes. I just
2	picked one of those other ill-defined sites
3	because we hadn't seen that before. So I
4	think I've got that covered.
5	MEMBER CLAWSON: Okay.
6	MEMBER MUNN: And I guess I had
7	chosen 444 instead of I actually chose 444
8	and 445, thinking it would be interesting to
9	see the difference in the 2 sites, both bone
10	cancer.
11	MEMBER GRIFFON: Well, actually,
12	444 might be better than 443. I assumed that
13	it was going to be the same model.
14	MEMBER MUNN: Yes.
15	MEMBER GRIFFON: But yours is much
16	more years worked. So I would be willing to
17	not do 443, pick 444 instead.
18	MEMBER MUNN: Okay. Great.
19	MEMBER GRIFFON: Okay. Page 14 I
20	have 453 I don't think we've done that site
21	457; 460 because it's very close well,
22	it's actually 45 percent 464; and 466.

1	MEMBER PRESLEY: Mark?
2	MEMBER GRIFFON: Yes?
3	MEMBER PRESLEY: Four seventy-one
4	is a 49.3, Paducah, with non-melanoma skin
5	basal cell, didn't work but 3 years
6	MEMBER GRIFFON: Three years.
7	MEMBER PRESLEY: but worked in
8	the early days.
9	MEMBER GRIFFON: Okay. I'm willing
10	to add it on to look. And sometimes we also
11	find that even though they say full
12	internal/external, they end up being
13	overestimating a purchase. So we might triage
14	some of these out, but okay.
15	Page 15, 480, 482, 485, 487, 488,
16	489. There are a couple of sites I wasn't
17	sure we have done: United Nuclear Corp and
18	Uranium Mill in Durango. That is why I picked
19	those.
20	MEMBER PRESLEY: I've got 447
21	simply for the fact that it's
22	MEMBER GRIFFON: Four seventy-four

1	you mean?
2	MEMBER PRESLEY: Four
3	seventy-seven.
4	MEMBER GRIFFON: Four
5	seventy-seven?
6	MEMBER PRESLEY: It's very high.
7	We've got a lot of Rocky. This guy has got a
8	lot of years, person. Again, it's a
9	MEMBER GRIFFON: Okay. Four
10	seventy-seven.
11	MEMBER CLAWSON: The only one that
12	I had that you didn't was the 488. It was a
13	thyroid.
14	MEMBER GRIFFON: I had 488.
15	MEMBER CLAWSON: Oh, do you?
16	MEMBER GRIFFON: Yes.
17	MEMBER CLAWSON: I guess I was
18	wrong. Sorry.
19	MEMBER MUNN: So would you read the
20	numbers on that page again, please?
21	MEMBER GRIFFON: Four
22	seventy-seven, 477, 480, 482, 485, 487, 488,

1	and 489.
2	MEMBER MUNN: Thank you.
3	MEMBER GRIFFON: All right. Page
4	16. I have 491, 500, 501, and 504.
5	MEMBER PRESLEY: What about 502?
6	It's close. It's only got six years, but it's
7	at Blockson.
8	MEMBER GRIFFON: Six years.
9	MEMBER PRESLEY: Building 55.
10	MEMBER GRIFFON: Okay. Five-o-two.
11	MEMBER GIBSON: What about 507?
12	MEMBER GRIFFON: Yes.
12	MEMBER GRIFFON: Yes. Five-o-seven, I think that's a new place we
13	Five-o-seven, I think that's a new place we
13	Five-o-seven, I think that's a new place we haven't looked at, International Minerals.
13 14 15	Five-o-seven, I think that's a new place we haven't looked at, International Minerals. MEMBER BEACH: Mark, have we done
13 14 15 16	Five-o-seven, I think that's a new place we haven't looked at, International Minerals. MEMBER BEACH: Mark, have we done much at Sandia?
13 14 15 16 17	Five-o-seven, I think that's a new place we haven't looked at, International Minerals. MEMBER BEACH: Mark, have we done much at Sandia? MEMBER GRIFFON: Yes, we have done
13 14 15 16 17	Five-o-seven, I think that's a new place we haven't looked at, International Minerals. MEMBER BEACH: Mark, have we done much at Sandia? MEMBER GRIFFON: Yes, we have done several.
13 14 15 16 17 18 19	Five-o-seven, I think that's a new place we haven't looked at, International Minerals. MEMBER BEACH: Mark, have we done much at Sandia? MEMBER GRIFFON: Yes, we have done several. MEMBER MUNN: Yes. We've done some

1	MEMBER GRIFFON: Five-o-six.
2	MEMBER MUNN: Well, we've got one
3	up in 491.
4	MEMBER BEACH: Okay.
5	MEMBER GRIFFON: Yes, yes. So we
6	won't include that if that's okay.
7	MEMBER BEACH: That's fine.
8	MEMBER GRIFFON: Page 17, I have
9	509, 512, 513, and 522. I had a question on
10	this Carborundum Company, but I thought we
11	might want to wait on that one because this is
12	.6 years worked. We might see some other
13	cases from that. But I don't think we have
14	done that site before.
15	MEMBER MUNN: That was very short
16	years worked.
17	MEMBER GRIFFON: Yes.
18	MEMBER PRESLEY: That was an early
19	Union Carbide site.
20	MEMBER GRIFFON: That's right. Do
21	we want to add that one? I'm open. We can
22	always get it at another.

1	MEMBER PRESLEY: Yes.
2	MEMBER GRIFFON: So right now it
3	stands at 509, 512, 513, and 522.
4	MEMBER MUNN: Good.
5	MEMBER GRIFFON: On page 18, I have
6	524, 525, and 535.
7	MEMBER CLAWSON: I had 540 just
8	because it was so close and only 2.2 years.
9	MEMBER PRESLEY: That's why I've
10	got 540 and 542 marked.
11	MEMBER GRIFFON: Okay. Five forty
12	and '42.
13	MEMBER PRESLEY: Yes.
14	MEMBER GRIFFON: Okay. They're
15	both close, and they're both a lot of years
16	yet.
17	MEMBER MUNN: I marked 537 because
18	I thought, hmm, that was a squeaker.
19	MEMBER GRIFFON: Yes. Yes. Okay.
20	That's okay. Five thirty-seven.
21	And last page, I have 545 and 547.
22	I would almost say we don't really need to go

1	to the random list because I think we have
2	more than enough here, but if anybody has any
3	on the random list that they're really wedded
4	to, you know, I guess we can add them on. But
5	otherwise I think we have plenty here to get
6	our 38.
7	So we will leave it at that unless
8	is everybody okay with that? All right. I
9	will get this list to Stu, then.
10	CHAIRMAN ZIEMER: We'll take it by
11	consent that that is the list. And we need to
12	formally authorize the Subcommittee to task
13	SC&A with their final selections from this
14	group that we have just authorized. Is there
15	a motion to that effect?
16	MEMBER PRESLEY: So moved.
17	CHAIRMAN ZIEMER: Seconded?
18	MEMBER GIBSON: Second.
19	CHAIRMAN ZIEMER: Any discussion?
20	(No response.)
21	CHAIRMAN ZIEMER: All in favor,
22	aye?

1	(Chorus of ayes.)
2	CHAIRMAN ZIEMER: Any opposed, no?
3	(No response.)
4	CHAIRMAN ZIEMER: Motion carries.
5	Thank you.
6	Let's next pick up the Blockson
7	discussion that we agreed yesterday would
8	carry over to today. Yesterday Mark Griffon
9	presented his concerns about the radon model.
LO	Jim Neton talked with us further about the
l1	radon model.
12	It was my understanding that Dr.
L3	Melius may have had some other questions or
L4	concerns to raise about Blockson. And I think
L5	it would be appropriate, Jim, if you shared
L6	those at this time as well.
L7	MEMBER MELIUS: Yes. Two things.
L8	One, specifically, I had made the suggestion
L9	to Jim Neton that they look into whether NIOSH
20	would have some industrial hygiene data from
21	the many industrial hygiene surveys they had

done that might be used to help validate part

of the Blockson model since there might be an industrial process that would be similar where area personal monitoring samples have been might help collected us look at the That particularly goes to this parameters. issue of whether individuals in that kind of facility, how well they will be reflected by sort of a general area model, which is what is used there.

I think Jim replied back to me that he didn't think that was feasible, partly on the chemical and physical, more physical properties and whether they could locate one.

I don't know how hard they tried that exactly.

I think my more general concern about it is still we have a model that has been developed in the absence of actual data and something that is going to be applied or actual very limited data to base it on. It's essentially some estimates based on source term.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

an appropriate method for estimating or reconstructing, doing dose reconstructions, and even more so given that they are planning to use this model for other sites. And I still think that some validation of the model is necessary before we can go forward with that.

My understanding, I wasn't here yesterday, but Mark raised a number of other technical questions about the model itself and the parameters used in that. I think those continue to concern me.

And, again, if this is something that been going be widely has to used throughout the dose reconstruction process at this and other sites, then I think some further work is needed before it can accepted.

CHAIRMAN ZIEMER: Thank you for those additional comments. Also, for my clarity here, in the Work Group, I believe

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

SC&A also reviewed the model at some point or
did they not? John, can you report? And if
they did, what was SC&A's evaluation of that
final model or did they?
DR. MAURO: As you recall, the
model that has been adopted was originally a
model that SC&A developed to review a number
that was developed quite some time ago.
And we developed the model, just
checked the number. And it sort of matured to
the point where now -
CHAIRMAN ZIEMER: Right. And so it
morphed into
DR. MAURO: Yes. So now NIOSH has
adopted it. So we are in an unusual position.
CHAIRMAN ZIEMER: Right.
DR. MAURO: Nevertheless, I was
just going to say that, of course, Mark copied
us on his questions. Jim copied us on the
answers. We were not tasked to look at any of
that.

Of course, we read it. Of course,

1	I did discuss this with Bob Anigstein, who was
2	our lead analyst. So no, we have looked at
3	it.
4	And we discussed it. We have
5	talked about it. But no. We were never
6	tasked to look specifically at the questions.
7	CHAIRMAN ZIEMER: No. I wasn't
8	asking that.
9	DR. MAURO: Yes.
10	CHAIRMAN ZIEMER: But the original
11	
12	DR. MAURO: Oh, the original
13	CHAIRMAN ZIEMER: model,
14	DR. MAURO: Yes.
15	CHAIRMAN ZIEMER: at least at
16	that point
17	DR. MAURO: Yes.
18	CHAIRMAN ZIEMER: there was some
19	level of agreement.
20	DR. MAURO: That model is the
21	equation, not the input parameters now, but
22	the equation is the model we developed. And

1 we think it is a robust model for 2 characterizing this Class of problem. CHAIRMAN ZIEMER: Thank you. And 3 those who do modeling, if there are any such 4 actually are 5 in the room who the modelers, what would be required to validate 6 7 such a model? Jim Lockey, do you have a comment or a question on it? 8 I just 9 MEMBER LOCKEY: have 10 question. Jim, when you look at 95 percent, is it geometric standard deviation that you're 11 looking at? 12 13 DR. NETON: Actually, we selected the 95th percentile of the output of the 14 15 dataset itself. It would be very close to 16 using the geometric standard deviation, which I believe is like about 2.7. 17 If you took the GSD to the 1.645 18 19 you would end up with the 95th power, And it would percentile of the distribution. 20 be fairly close to the 17, not exact, within a 21

picocurie or two per liter.

1	MEMBER LOCKEY: So close to the
2	geometric standard deviation?
3	DR. NETON: Well, no. It would be
4	close to the 95th percentile if we used the
5	geometric standard deviation to calculate the
6	95th percentile.
7	MEMBER LOCKEY: Okay.
8	DR. NETON: Because the GSD would
9	be like 64.5 or something like that or the
10	84th. I'm sorry. One GSD would be 84th
11	percentile on a normal
12	MEMBER LOCKEY: The exact
13	percentile
14	DR. NETON: What we did is we got
15	the output of the, I think it was 10,000 runs.
16	And we said
17	MEMBER GRIFFON: Sixty-five
18	thousand, I think.
19	DR. NETON: Sixty-five or whatever
20	or 100,000. I forget how many runs we had, a
21	large number of runs. We went to the 95th
22	percentile of all of the outputs that were

1	generated, running that calculation n times.
2	MEMBER GRIFFON: But you are right.
3	It is almost equivalent to
4	DR. NETON: It is very close, yes.
5	You could do it either way, but we felt
6	MEMBER GRIFFON: Right.
7	DR. NETON: we didn't want to
8	get into the dispute whether it was log-normal
9	or not. And we said just pick the 95th
10	percentile right off of the output dataset.
11	MEMBER LOCKEY: Correct me if I am
12	wrong, but when I have done modeling for
13	looking at exposure reassessments, if you use
14	close to standard, geometric standard
15	deviation, usually that value is anywhere from
16	10 to 100 times greater than if you used the
17	standard arithmetic mean standard deviation.
18	Is that correct or am I wrong on that?
19	DR. NETON: No. I don't think it's
20	100 times. It would depend on the individual
21	dataset. But the GSD
22	MEMBER LOCKEY: It depends on what

1 the means are and how much data you have. DR. NETON: Yes. 2 MEMBER LOCKEY: But I am trying to 3 4 get a handle on --Well, I mean, 5 DR. NETON: tell you that the geometric mean of the 6 7 distribution is about four. Four picocuries per liter would be our best guess, our best 8 estimate of the concentration in the 9 10 given the distributions that we put into the model. 11 Using a GSD of about, I think it 12 13 is, 2.7, the 95th percentile comes out about So it is a factor of almost four higher 17. 14 15 than what the geometric mean would be. 16 And that, as I have stated several times, is to account for the difference in the 17 variables that make the model and 18 up 19 particularly where the main driver building ventilation rate. We have modeled it 20 anywhere from one to five air changes per 21

hour.

And one small point of clarification. This is, in essence, the SC&A mathematical equation model. We do differ in several of the input parameters that we have used. Most notably the lower bound of the air turnover rate is one in our model versus .1 in SC&A's model.

As long as I am up here, one more point. We did have this model independently reviewed by Dr. Naomi Harley, who was an internationally and nationally recognized radon expert. And she agrees in substance with the concept of using this model, although she would have some issues with some of the input parameters that SC&A had proposed.

MEMBER LOCKEY: Thank you.

CHAIRMAN ZIEMER: Now, let me try to evaluate where we are in this. The Blockson issue is kind of, now the Blockson petition action is on the table. But we have this radon issue.

And the closure of the radon issue

NEAL R. GROSS

seems to be the critical point in terms of the next step. And it appears to me that the Board needs to determine whether it believes that it has enough information at this point to close the radon issue.

You have heard the questions that have been raised. You have heard the various responses. And if so, a motion, for example, to accept the NIOSH radon model as adequate or if the Board believes that there is additional work that needs to be done if these questions that have been raised reach a level in the Board's mind that requires further pursuit of these issues, then a motion to do something in response to that would be in order, which might also include a tasking issue.

So it is really in the Board's hands at this point. The main motion is on the table. And we have this radon discussion. But, as I talked about yesterday, we have got to come to closure one way or the other on

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Blockson.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

And so I want to push you to that point. And so you can push back now, but let's see if we can move one way or the other on this.

Wanda, do you have a comment or a question or an action? No. Mark?

MEMBER GRIFFON: I mean, I don't know that there is anything more that I would ask of NIOSH right now other than -- I mean, I know Jim Melius put a question on the table about other industrial, you know, but from my standpoint, at least as I was putting together my questions and looking at NIOSH's answers, it dawned on me that some of these -- I would actually like some time to go back to some of the original assumptions that are made in the model that I was kind of taking as absolutes. And now I am not so sure they are absolutes, such as the 6,000 tons per week throughput, which is obviously an important point on this if you have the source term wrong.

NEAL R. GROSS

And I may be wrong. And I am not asking NIOSH to provide anything else. I am just asking for an opportunity to review that information again because my sense just looking at it the last couple of nights is that that number is based on one memo from 1951. And if that is the case, I have more concerns about going forward with a source term-based model.

There are a number of things like that that I just want to double check. I am not saying the information is not there and hasn't been provided. You know, I just have to refresh myself on it and find it and look at it a little closer.

CHAIRMAN ZIEMER: Okay. You have heard Mark's comment that, again, I simply want the Board members to make a determination as to whether that concern rises to the level, in terms of the radon issue that you would believe we should take more time to do that.

I am pushing both ways. Make sure

NEAL R. GROSS

we cover concerns, but at some point concerns
-- one can always find issues that may be a
concern but may take years to resolve. So we
don't want to do that. I mean, we have a
responsibility also to make decisions.

So I want to push that and, yet, respect the concern. And it is not my decision. It is the Board's. So what would you like to do? Okay. People are pointing. Oh, Wanda has got her -- I was blocked off by the Lockey computer. Wanda, do you have a comment or an action?

MEMBER MUNN: I have a comment. We have worked on this site and on this model and on these questions, although the questions have evolved over time for well over two years.

It is difficult to be enthusiastic about newly discovered information in this model, which has not changed a lot. The radon issue was discussed thoroughly, I believe, in our previous discussion.

NEAL R. GROSS

Regardless of the number of documents we have to support whatever the input is, we have documentation to support it.

The model which was of concern has been duly reviewed by appropriately qualified individuals.

Our own contractor has indicated very clearly that they feel this issue is ready to move forward, that we have the right model and the right method for proceeding with Blockson. I would like to see us continue along that same path today and bring this to closure if we possibly can.

The Chair has asked that we separate the issues. One issue is whether you are ready to vote yet. And the other is, can we vote? I will leave that in his hands to pursue.

It appears almost futile to continue reviewing material which in recent months has not changed and has been available to us for a considerable period of time in

NEAL R. GROSS

1	almost any form we wish to observe it.
2	CHAIRMAN ZIEMER: Other comments or
3	questions or suggestions or actions?
4	(No response.)
5	CHAIRMAN ZIEMER: Actually, I am
6	wanting someone to make a motion. The motion
7	can be either way. We need to do something
8	here. Okay. Otherwise the Chair will suggest
9	a motion. Okay. Dr. Lockey?
10	MEMBER GRIFFON: It is on the table
11	right now.
12	CHAIRMAN ZIEMER: No, no. The
13	petition motion is on the table. We're not
14	talking about it. We're talking about what to
15	do about radon. If we could close the radon
16	issue, we would still need a motion for the
17	main petition to come off the table. Yes,
18	right.
19	MEMBER LOCKEY: In relationship to
20	this issue, I think, you know, that the
	l child ibbac, i chillin, jou mow, chac che
21	scientists at NIOSH and SC&A cannot reach a

reconstruction that is felt to be adequate from a scientific perspective by the majority of Board members.

Then this aspect of the SE evaluation by the Board is really an academic exercise with no achievable endpoint. There are consequences of this long delay in this SE final decision process, both for NIOSH as well as SC&A, in relationship to determining dose reconstruction in regard to frustration claimants and really unproductive professional time and resources by NIOSH, by SC&A, as well as the Board, as well as costs incurred by the Treasury.

I think we have to come to closure.

And if we are not going to be able to reach a level of scientific adequacy using our consultants and NIOSH, then we are at an impasse. And we are not serving anybody. So I think we have to bring this to closure.

CHAIRMAN ZIEMER: Larry?

MR. ELLIOTT: I would just like to

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

comment that NIOSH and OCAS have been involved in these deliberations. And we have accepted the model that was developed by SC&A.

We have moved from what our thinking was on how to bound this particular dose at this site and really have in place, we feel, an ability to bound this particular dose for Blockson workers in a claimant-favorable way.

The target organ we are primarily concerned with here is lung cancer. This is actually going to compensate all of those lung cancers at Blockson as it stands.

It is a model that can be applied and source term inputs changed for like Texas City. Yes. But it will have to address the Texas City circumstances. Texas City is different than Blockson.

So we are thinking Blockson Chemical. We are proceeding with dose reconstructions on Blockson Chemical. And we think that we have come forward with a

NEAL R. GROSS

1	claimant-favorable bounding approach.
2	CHAIRMAN ZIEMER: Thank you.
3	And Dr. Lockey?
4	MEMBER LOCKEY: And I concur. This
5	is a lung cancer issue primarily. It may be a
6	lymphoma issue in certain cases, but it is a
7	lung cancer issue primarily.
8	In looking at the 95 percent
9	deviation, I think it is a very
LO	claimant-friendly model for that particular
L1	cancer.
L2	CHAIRMAN ZIEMER: Okay. There are
L3	a couple of possible motions. I have already
L4	indicated what they are. One is to move to
L5	accept the radon model that has been provided.
L6	And then we would move to the main motion,
L7	which is on the table, or to direct some
L8	further action with respect to the questions
L9	that have been raised about radon.
20	Wanda Munn?
21	MEMBER MUNN: I am willing to move
22	that we accept the radon information that has

1	been provided to us as adequate and move on.
2	MEMBER ROESSLER: I second.
3	CHAIRMAN ZIEMER: You have heard
4	the motion. It is open for discussion. Dr.
5	Melius?
6	MEMBER MELIUS: I think we have
7	said everything. I don't want to lengthen
8	this, but I will state for the record that I
9	continue to think that this model has not been
10	adequately validated and has not been
11	demonstrated.
12	I think it could be and there could
13	be steps that NIOSH has taken and they
14	haven't. And until I see adequate
15	information, I am not willing to accept this
16	model.
17	CHAIRMAN ZIEMER: So you are
18	speaking against the motion?
19	MEMBER MELIUS: Correct.
20	CHAIRMAN ZIEMER: Any others who
21	wish to speak for or against the motion?
	wish to speak for or against the motion.

1	CHAIRMAN ZIEMER: Then I assume we
2	may be ready to vote on the motion. Okay. If
3	you vote aye, you are voting to essentially
4	end the debate on the radon issue. And then
5	we would not necessarily need to move to the
6	next step today, but the next step would be to
7	move to bring the petition from the table.
8	Okay. So all who favor the motion
9	regarding the radon issue well, let's roll
10	call vote it.
11	MEMBER CLAWSON: Yes is accepting
12	and no
13	CHAIRMAN ZIEMER: Yes is accepting.
14	MR. KATZ: Ms. Beach?
15	MEMBER BEACH: No.
16	MR. KATZ: Mr. Clawson?
17	MEMBER CLAWSON: No.
18	MR. KATZ: Mr. Gibson?
19	MEMBER GIBSON: No.
20	MR. KATZ: Mr. Griffon?
21	MEMBER GRIFFON: No.
22	MR. KATZ: Dr. Lockey?

1	MEMBER LOCKEY: Yes.
2	MR. KATZ: Dr. Melius?
3	MEMBER MELIUS: No.
4	MR. KATZ: Ms. Munn?
5	MEMBER MUNN: Yes.
6	MR. KATZ: Dr. Poston?
7	MEMBER POSTON: Yes.
8	MR. KATZ: Mr. Presley?
9	MEMBER PRESLEY: Yes.
10	MR. KATZ: Dr. Roessler?
11	MEMBER ROESSLER: Yes.
12	MR. KATZ: Mr. Schofield?
13	MEMBER SCHOFIELD: No.
14	MR. KATZ: Dr. Ziemer?
15	CHAIRMAN ZIEMER: Yes. Then I will
16	declare that the motion fails since there is
17	not a majority. The motion having failed
18	means that we are obligated in the Chair's
19	mind to address the issues that have been
20	raised. So let me suggest a path here.
21	Mark, you have indicated a
22	willingness to review the issues that you have

1	raised. I think that part is pretty much in
2	your hands.
3	We have removed this from the Work
4	Group in any event. It is at the Board level.
5	So if you will agree to address those issues
6	and report back to the Board?
7	MEMBER GRIFFON: I am willing to do
8	it in the same process I did before.
9	CHAIRMAN ZIEMER: And, Jim, in
10	terms of the issues you raised, I am not sure
11	how to proceed there. I think in terms of
12	finding industrial hygiene data that you
13	suggested to Jim, I think Jim has indicated
14	that NIOSH does not believe that that would be
15	fruitful.
16	The other part is the validation
17	issue. Actually, I am always for validating
18	models. So in principle, I am fine with that
19	concept. It is not clear to me how we do that
20	in this case, unless you had a suggestion.
21	MEMBER MELIUS: One thing to be
22	considered that may require work on the part

of NIOSH is to look at other situations where there may be radon data available that might be useful.

Secondly, a more indirect way of validating this and us better understanding how the model would be applied would be to apply it to the Texas City situation and given what information is there since that appears to be their intent.

And I think that would also -could be helpful in us understanding the model
if there is not adequate sampling data
available in appropriate facilities to be able
to validate the model.

CHAIRMAN ZIEMER: Jim Neton?

DR. NETON: I would just like to comment on Dr. Melius' first suggestion. I think in our responses to Mark Griffon's questions, one of the analyses that we did was to compare the 17 picocuries per liter we proposed against all of the existing radon data we could find that was as close in time

NEAL R. GROSS

to the Blockson situation as possible. And that was provided as attachment 1 to our responses.

In fact, all of those values were close to an order of magnitude or more below the values we were proposing, acknowledging the fact that there were different time frames and such and sort of talking about how the ventilation rates would have been substantially different in order to get those low values.

CHAIRMAN ZIEMER: Well, you have made some suggestions relating to validation.

And we are not in a position I don't think to task NIOSH to do some of this, but perhaps Jim and Larry, you can give some thought to what might be done.

Do we have a copy of the Naomi Harley report? I am trying to remember if that was distributed to us.

DR. NETON: Yes, I am pretty sure you have a copy of it. That was an analysis

NEAL R. GROSS

of actually the input parameters. But tacit in that analysis was an endorsement of the approach itself, which was to the probabilistic model.

CHAIRMAN ZIEMER: I don't know if any other Board members have suggestions on this. It may be that where we will have to leave it today is proceed with Mark's issues and maybe in our phone call meeting, which comes before our next meeting, we can have something more definitive.

I would ask that without tasking, both to ask NIOSH and to ask our contractor for suggestions on how we might proceed on what we might call validation. And different people have different ideas on actually what validation is. So we would have to sort of agree to what it means to validate a model, but -

MEMBER MELIUS: And I agree. I will try also to make some more specific recommendations to NIOSH about what I mean and

NEAL R. GROSS

am looking for and expecting in validation.

CHAIRMAN ZIEMER: Yes. Because I think to some extent -- and I am sort of -- this is intuitive, too. If you feel uneasy about a model, you feel like something needs to be done to relieve that uncertainty. But it is not always clear how you do it.

I mean, there are formal ways of validating models that engineers and others have. And whether this applies, I don't know.

MEMBER MELIUS: But there's also issues related to -- there may be parts of the model that can be validated or certain aspects of the model where there is available data. That is what I have been trying to look for.

I think we have recognized that there are limited data available to do this. It's not like there's a whole universe of thousands of similar buildings where there's tons of data collected and so forth that can be done, but there may be situations where at least parts of this probabilistic model can be

NEAL R. GROSS

validated or at least we can have more confidence in the results from that model.

CHAIRMAN ZIEMER: Larry?

MR. ELLIOTT: Well, we certainly would welcome any suggestions that any of the Board members have about how to examine this model for a sense of sanity and reality and realism.

We have talked about Dr. Melius' suggestion, but I would offer that the data that is collected and is NIOSH holdings and as an industrial hygienist for 30 years at NIOSH, I am pretty familiar with the different types of data that have been collected, different purposes for collecting that data as well.

Under those purposes, the data may lend itself to this kind $\circ f$ not. an examination. So you have to understand that going into it. And I'm sure that understands that. He has worked at before. He knows the datasets that talking about.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

So we're not resistant to attempts to validate, but we want to be very clear about what validation means, as you have pointed out. And we want to be very clear about how we would go about that. So if you have suggestions, we certainly would welcome them.

I am going to offer this, though.

I really would like to see a consensus of the Board to that end because this next year is very difficult for us trying to achieve our management objective and balance all of the resources that we have got.

And, quite frankly, you know, when we look again at the target organ that is primarily affected here and understand that this model is -- in my mind, it approaches the implausible aspect of bounding almost, 17 picocuries. You know, that is a lot in a building, extremely high level of radon inside a building that is generally an open air building, to be quite frank about it.

NEAL R. GROSS

1	So, you know, I am hard-pressed to
2	say that, on one hand, I find that we come
3	forward with a claimant-favorable and
4	reasonable estimate when it approaches the
5	implausibility bound. And we are going to try
6	to validate something about that.
7	So I sense that we need Board
8	consensus to direct or to ask NIOSH to pursue
9	this to great ends because I have to balance
10	the resources that are given to me.
11	Quite frankly, we're moving forward
12	with Blockson claims. We are seeing Blockson
13	claimants with lung cancer get compensated
14	through not only this model, but when this
15	model is added, they definitely are going to
16	be compensated.
17	So I guess I would leave you with
18	the question, to what benefit?
19	CHAIRMAN ZIEMER: Yes. Thank you
20	for that comment.
21	Dr. Lockey?
22	MEMBER LOCKEY: And I would state

1	the same thing, that the model is very
2	claimant-friendly for lung cancer. And radon
3	is a cause of lung cancer. And it is not
4	clear as to why we would want to go ahead and
5	invalidate this because it is a very
6	claimant-friendly approach. So I concur.
7	MR. ELLIOTT: I think one of the
8	risks that I see in an attempt to validate is
9	it will drive perhaps the model the other way.
10	That is a possibility.
11	MEMBER MUNN: Highly likely.
12	CHAIRMAN ZIEMER: And Jim Neton?
13	DR. NETON: I can't resist. A
14	couple of things. One is a point of
15	clarification. I think almost all of the lung
16	cancer cases at Blockson Chemical have been
17	paid already based on not the radon model but
18	the claimant-favorable nature of the uranium
19	inhalation model.
20	I don't know that this model when
21	added would change one case. I don't know

I don't think it would. But that is

that.

probably not relevant.

Oh, gee. I lost my train of thought here. That was a major point, too.
Oh, we have sort of come full circle here because if you remember -- and John Mauro pointed this out -- the original point of this model was to validate the original NIOSH number that was being used, which was around two picocuries per liter.

And the issue was raised, well, that number seems low. And we concurred that Florida phosphate plants, which is what it was based on, was probably not a good surrogate.

But, nonetheless, the original model came out and said, well, the medium value is not too bad. The model sort of validated that two to four picocuries per liter seemed to be a reasonable number in a plant with reasonable ventilation parameters.

So we have kind of validated the original numbers we were using. And now we are going back and saying, well, we need to

validate the model that was used to validate the original numbers. I guess at this point we have come full circle here.

And, again, I have provided the data from all of the relevant radon studies that I could find from the 1970s and '80s that, in my opinion, clearly validate that the model parameters are claimant-favorable; that is, 17 picocuries per liter versus almost the highest you can get in an operating floor is about .4 picocuries per liter in a phosphate plant, even in Idaho.

CHAIRMAN ZIEMER: Okay. Thank you for those additional comments. So where this is, then, is that the petition remains on the table. Mark will be looking at the items that he discussed. The validation issue is still a fuzzy item.

We don't have any specific actions on that other than for Dr. Melius, who raised the validation issue to consider what the validation means as far as he is concerned for

NEAL R. GROSS

ideas if either NIOSH or SC&A without detailed tasking comes up with some ideas of what they might suggest as a direction or Board members.

And I will ask the designated federal official to put this item on the next agenda, not the next full-face meeting but the phone agenda, and see if we can't try to close this issue.

Even after this issue is closed, we still have the thorny matter of the petition itself, which, as you recall, was also a split vote. And that is of concern as well. But we need to close this matter one way or the other.

So thank you very much for that.

Let's move ahead here. We passed our adjournment deadline. So we have got to really move quickly on this one.

Oak Ridge Hospital. We agreed to establish a work group. I have had already a number of individuals volunteer for that.

They include Robert Presley, John Poston, Jim

NEAL R. GROSS

1	Lockey, Phil Schofield. And was there one
2	other one?
3	MEMBER ROESSLER: I volunteered.
4	CHAIRMAN ZIEMER: Gen Roessler,
5	right. Those were the five that I had
6	already. Is that six? That's five. I had
7	some interest, but I think I will set aside to
8	this group of experts.
9	I think I would like to ask Dr.
10	Lockey to chair that if he would be willing to
11	do that.
12	MEMBER LOCKEY: That would be fine.
13	CHAIRMAN ZIEMER: Okay. The charge
14	for that group would be to examine the
15	Evaluation Report. I can't remember if we
16	felt we needed SC&A assistance on that. Where
17	did we stand on that? I think the Work Group
18	will determine whether they need assistance on
19	that after they meet and delineate what the
20	issues are.
21	So we will charge the Work Group
22	with examining the petition, evaluation review

1	of the petitions. And then if tasking is
2	needed, they can let us know.
3	Is that agreeable?
4	(No response.)
5	CHAIRMAN ZIEMER: Any objection on
6	the part of the Board? And, Larry, a comment
7	or question.
8	MR. ELLIOTT: I would just like to
9	hear what the expressed issues are because
10	there were two that I understood
11	CHAIRMAN ZIEMER: Exactly.
12	MR. ELLIOTT: that were on the
13	table.
14	CHAIRMAN ZIEMER: That was the
15	other half of this one. We said that we would
16	delineate what the issues were. And somewhere
17	I thought I had a list of those.
18	MEMBER PRESLEY: One issue was the
19	completeness of the data of the
20	CHAIRMAN ZIEMER: Let's jot these
21	down.
22	MEMBER LOCKEY: The other issue was

class definition.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

CHAIRMAN ZIEMER: Well, it was the Class definition from two aspects. One was, was it inclusive enough to include? there have been outside individuals who were not specifically under contract or that period but who were working there, such particularly doctors, and also whether there were individuals who were hospital employees that could not have, although I think there is some evidence that it would be pretty hard to determine that. But the Work Group can look at that.

So it is the definition of the Class. What were the other issues?

MEMBER GRIFFON: I think there was some question. John. I think John raised the question of whether the record search was exhausted and whether there are dosimetry records. I think that was your point.

CHAIRMAN ZIEMER: Well, certainly I am assuming that the NIOSH OCAS staff person

1	will be a resource to this group. And that
2	would be is that Dr. Hughes?
3	MEMBER BEACH: Lara Hughes.
4	CHAIRMAN ZIEMER: Yes, yes. So,
5	Larry, am I correct in assuming that Dr.
6	Hughes would be the resource person from
7	NIOSH?
8	MR. ELLIOTT: Yes, that is correct.
9	CHAIRMAN ZIEMER: Right.
10	MR. ELLIOTT: I wonder. Can I ask
11	again to get a little sharper edge on this
12	issue of the Class definition? If the issue
13	goes to what I heard you talk about, Dr.
14	Ziemer, about are there physicians that worked
15	there at that hospital during that time that
16	were not AEC-employed, I'm not sure how that
17	goes directly to the Class definition that we
18	have established. It goes to the eligibility
19	of filing a claim, which is DOL's authority.
20	CHAIRMAN ZIEMER: Right, right,
21	right.
22	MR. ELLIOTT: So if that is not it,

1	what is the Class definition issue? I mean,
2	if we take that aside, I mean, I think you can
3	examine that.
4	CHAIRMAN ZIEMER: Yes.
5	MR. ELLIOTT: I am not advocating
6	you shouldn't examine that.
7	CHAIRMAN ZIEMER: Yes.
8	MR. ELLIOTT: But I am saying that
9	if that is part and parcel of the issue of who
10	is in the Class and who is not, that is a DOL
11	eligibility issue. And it would help them to
12	understand that there might have been
13	physicians or people who worked in the
14	hospital but were not AEC-employed. Do you
15	see my distinction I am trying to draw?
16	CHAIRMAN ZIEMER: Yes. Right,
17	right, right.
18	MR. ELLIOTT: So that is not Class
19	definition. That is class eligibility. And
20	that is DOL's purview. The Class definition
21	if you are trying to understand is it too

broad or is it too narrow, I think that is

1	your charge.
2	CHAIRMAN ZIEMER: Right.
3	MR. ELLIOTT: Okay.
4	CHAIRMAN ZIEMER: And I think that
5	is the framework we are talking about: too
6	broad or too narrow.
7	So that was one issue. What was
8	the second one?
9	MR. KATZ: The second issue was
10	whether the record search has been sufficient.
11	And sort of related to that, I think Dr.
12	Poston was questioning whether there are
13	substantial exposures to be credited, in
14	effect, I guess.
15	MEMBER PRESLEY: Where all the
16	strings have been pulled, simple fact.
17	CHAIRMAN ZIEMER: Were there any
18	other issues that Gen?
19	MEMBER ROESSLER: I had to take a
20	brief break, but I think I had a question
21	about interviewing people, whether the
22	interview list of the people who might have

1	been familiar, that it was complete and I
2	don't know if you brought that up as
3	complete as can be.
4	CHAIRMAN ZIEMER: Okay. Basically
5	this work group may simply need to go into
6	more depth with Dr. Hughes. You may find that
7	all of the issues have been covered and you
8	can report back or if not, what are the open
9	strings?
10	Dr. Lockey, are you sufficiently
11	clear on that, too, as chair?
12	MEMBER LOCKEY: I am clear.
13	CHAIRMAN ZIEMER: He's clear.
14	MEMBER LOCKEY: That is about the
15	only thing I am clear about, but I am clear.
16	CHAIRMAN ZIEMER: I am going to
17	postpone formalizing our transcript policy
18	until next time because I don't want to have a
19	discussion because there is one thing that we
20	have to do, I think. I could postpone it to
21	the telephone thing, but you have on your

table a draft response to the Higgins letter.

I call it the Higgins because it was Representative Higgins' office that read the original record or original letter into the record earlier this week. The letter was signed by Senators Schumer and Gillibrand, by Representative Higgins, Representative Slaughter, Representative Massa, and Representative Lee.

you all have a copy of proposed response letter? The response letter basically acknowledges receipt of their letter, indicates it was distributed to all members of the Board and read into the record. It acknowledges their request to consider Buffalo as a future meeting and indicates we are considering that. No promises were made, are considering but. we that. That was discussed already.

have added paragraph here а acknowledging realize that that we the claimants have had frustrations. And I have framed that in of general sort terms.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Claimants, both at that site as well as others, are concerned about both the process and the times. And we acknowledge that.

I point out -- and often this gets overlooked. And I hope it is okay to say this. And I need the exact number, but I pointed out here that a large number of the claims have been successful, Bethlehem Steel, and indicate that dose reconstructions have been carried out because the implication often in these letters is that nothing has happened.

And I have indicated here that some
-- and I have put in as a holder 40 percent,
but I don't -- we will get the exact number of
the claimants have actually been compensated.

And I think it is important to particularly some of the representatives here we have not had interactions with before and to make sure that they are aware of that, that there has been action already at Bethlehem and then simply thank them for their interest in the program.

NEAL R. GROSS

So I would like to ask if this letter is acceptable. I will send it. If you want changes, so indicate.

Wanda?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

It is incumbent upon MEMBER MUNN: this Board to make every effort to make sure that all of the parties who have any interest in it are correctly informed. We have not correctly informed Congress in my view since we initiated this program with respect to what realities are, including a figure which is -not only is including the figure an excellent idea, but it is also an excellent idea to, probably not a political idea, but it would more than likely be a very truthful idea to include at some juncture, not in this letter. we might consider in later But letters indicating what the rate of such occurrences are in the general population. That is not generally known.

CHAIRMAN ZIEMER: Okay. Thank you.

Yes, Jason?

1	MR. BROEHM: I just wanted to see.
2	The Board has not yet decided on the May 2010
3	meeting location?
4	CHAIRMAN ZIEMER: No. We have not
5	decided on that. I think we agreed to
6	postpone that until, was it, the next, the
7	full meeting. Which meeting are we talking
8	about?
9	MR. KATZ: We did target Buffalo
10	for May. I would say that we have done some
11	preliminary looking at hotels and are having a
12	little bit of difficulty with the dates
13	because it is a Wednesday, Thursday, Friday
14	schedule.
15	And we can't really revisit that
16	date given we have already lost members here.
17	But that apparently is a problem with some of
18	the hotels that could accommodate the meeting.
19	So tentatively at least we have
20	penned in Buffalo for May.
21	MR. BROEHM: Okay.
22	CHAIRMAN ZIEMER: I thought we had

1	both Buffalo and Washington as possibilities.
2	But, in any event, I think this is still a
3	correct statement. We are not locked. We
4	don't have a final.
5	MR. BROEHM: Right. I guess I just
6	wanted to get at whether you could say
7	something more positive than we are taking
8	this under consideration. I don't know if you
9	want to commit yourself at this point given
LO	that we don't know about hotel availability,
11	but you could say something stronger, like,
L2	we're looking into Buffalo possibly for the
L3	May meeting, something along those lines that
L4	might more fully address their question and
15	request. I leave that to the Board to
L6	CHAIRMAN ZIEMER: Yes, we are
L7	certainly willing to do that. We could say
L8	something like, we are considering it for our
L9	what meeting was it?
20	MR. KATZ: May.
21	CHAIRMAN ZIEMER: our May
22	meeting if we are able to arrange a hotel or.

1	if not, a subsequent meeting.
2	MR. KATZ: Yes. I mean, I hate to
3	sort of raise their expectations at this point
4	until we can pin that down. So I would rather
5	under-promise and over-deliver than the other
6	way.
7	MEMBER LOCKEY: I concur with that.
8	I am happy the way the language is.
9	CHAIRMAN ZIEMER: Okay. Well, let
10	me ask you, are there any concerns about
11	anything in the letter? Brad?
12	MEMBER CLAWSON: Just for Mound,
13	were we going to get the exact number and put
14	in there?
15	CHAIRMAN ZIEMER: Yes. Larry is
16	going to give me that. That is kind of a
17	placeholder. I know it is very close to 40.
18	When I drafted this, I didn't have it. There
19	is probably a more recent number than I would
20	have anyway. But it is very close to 40.
21	MEMBER CLAWSON: And I understood
22	that.

1	CHAIRMAN ZIEMER: And I will put in
2	the exact value, yes. Can I take it by
3	consent that this is all okay? We still have
4	a quorum here.
5	MEMBER CLAWSON: Yes.
6	CHAIRMAN ZIEMER: If there are no
7	objections, I will draft a final copy of this
8	letter.
9	MEMBER MUNN: Please.
10	CHAIRMAN ZIEMER: Okay. Ted, help
11	me out here. We are going to defer
12	formalizing our transcript policy until later.
13	You had something else, though.
14	MR. KATZ: I have a couple of other
15	things, but having lost some members and all,
16	I am not sure what you want to do with them.
17	One, with respect to tasking SC&A,
18	there are a number of SECs going forward that
19	will be delivered for October for which you
20	don't have a Site Profile review.
21	So I am just raising the question
22	as to whether you want to consider tasking

SC&A to do a Site Profile review knowing that those will come before the Board in October.

And some of them I gather from conversations with John Mauro are relatively simple sites. So they probably don't warrant that sort of work but really would be fine to have a response of SC&A action if you need it after you have the SEC evaluation delivered.

The two that he raised with question marks because they are perhaps more complex sites -- and Jim Neton can speak to that if that is characterizing that -- are United Nuclear and Piqua. John thought those might be more complex and you might want a head start on those. But again, Jim, can you help us with this?

DR. NETON: Piqua, I don't think is very complex. It was a fairly short operation of a nuclear reactor in Ohio. But United Nuclear I am not sure. I am drawing a blank on that one. It could be Piqua.

MEMBER MUNN: They do a lot of

NEAL R. GROSS

1	stuff.
2	MR. KATZ: So then the question is
3	whether for United Nuclear you want to task
4	SC&A to do a Site Profile review. You haven't
5	tasked that many Site Profile reviews under
6	the new contract at this point as a way of
7	sort of getting the Board ready for hearing
8	SEC petition evaluation in October.
9	CHAIRMAN ZIEMER: I certainly think
10	it is in order. Any comments, Board members?
11	Any objection to proceeding with that
12	tasking, realizing that that is on the horizon
13	in any event?
14	(No response.)
15	CHAIRMAN ZIEMER: I take it by
16	consent that we are free to go ahead and task
17	SC&A on that one.
18	MEMBER MUNN: Yes.
19	CHAIRMAN ZIEMER: Are there other
20	tasking things we need to address, Ted?
21	MR. KATZ: Not at this I mean,
22	the other ones that he raised I will just

1	raise to your attention, but we can revisit.
2	The TBD-6000, the first few appendices SC&A
3	has looked at, but there are a number of other
4	appendices they haven't. There has been no
5	tasking so far for those other appendices.
6	And then the other sites of
7	interest are PNNL - there has been no SC&A
8	look at that Kansas City and Simonds Saw.
9	So I just wanted that. SC&A provided
10	information on this, but I want to bring that
11	to your attention.
12	CHAIRMAN ZIEMER: Did we task SC&A
13	on Appendix C, which is Madison? We did that
14	already, didn't we?
15	MEMBER BEACH: Yes.
16	CHAIRMAN ZIEMER: Yes. So he is
17	talking about the rest of them. And they are
18	involved in Appendix B as well already. So it
19	is the remaining. But we don't actually need
20	to do that today apparently.
21	MR. KATZ: We don't need to. You

look

to

could

task

them

other

at the

1	appendices.
2	CHAIRMAN ZIEMER: Most of those are
3	actually fairly brief. Remind me, how many
4	are there: A, B, C?
5	DR. NETON: A lot. It goes through
6	double letters.
7	MEMBER GRIFFON: I think we should
8	consider those in the 6000 Work Group.
9	CHAIRMAN ZIEMER: Yes. Let the
10	6000 Work Group take a look and see which
11	ones, yes, because there are a lot of small
12	ones there.
13	MEMBER CLAWSON: Explain to me.
14	PNL? Pacific National Labs?
15	MEMBER MUNN: Pacific Northwest
16	National Laboratories.
17	MEMBER CLAWSON: Now, was that part
18	of Hanford or is this different?
19	MEMBER MUNN: Yes. No, it is not a
20	part of Hanford. They are a separate
21	laboratory. They are a national laboratory
22	outside of the Hanford site.

1	MEMBER CLAWSON: Okay.
2	MEMBER MUNN: They work with the
3	Hanford site, but they are a separate
4	laboratory.
5	MEMBER CLAWSON: Okay. That's what
6	I wanted to clarify because I was under the
7	impression that they were the same.
8	MEMBER MUNN: No.
9	CHAIRMAN ZIEMER: We're rapidly
10	losing people. I think if there is further
11	tasking, we will need to do it in our phone
12	meeting.
13	MR. KATZ: So that takes care of
14	tasking.
15	The other thing I just would raise,
16	but I think at this point we can't really deal
17	with it, is as far as whether we need other
18	work groups. Did we establish any work group
19	for the Oak Ridge Hospital? And that I guess
20	will be a brief exercise.
21	The other sites where we have SC&A
22	Site Profiles but we don't have any resolution

process with the Board, just to note them for the record at this point, -- and I'll remind you at the next Board meeting -- K-25, X-10, Portsmouth, Sandia, Albuquerque, ANL-East, and Weldon Springs. None of those are currently under any kind of resolution process in looking at the Site Profiles.

And I would just note, then, of that list, K-25, I think Jim or somebody noted, maybe it was Larry, on Monday that that is one of the sort of highest fliers in terms of number of claims these days, I think K-25.

So we might want to think at least in the future Board meeting about whether we need a new work group or two to start taking on any of these. I know the Board has a lot of work.

CHAIRMAN ZIEMER: Yes. And, of course, we have a number of big sites that already are a little behind the eight ball as far as our ability to conduct work group meetings. But certainly we want to prioritize

NEAL R. GROSS

these.

Probably K-25 will be the next one that we will have to form. And even if we formed it now, I can't imagine any of our folks are going to be able to do anything about it before our next meeting in terms of - we have some big site groups that need to meet. We have Los Alamos. We have Savannah River. We have Hanford. So those are all kind of in the queue as well.

One final comment?

MR. KATZ: All right. So one last notice is that there was a person, a former Fernald worker, who couldn't make it the first two days for public comment who provided to the Board, provided to all the Board members a letter, in effect, from the former worker.

It relates to breast cancer and the site and studies of breast cancer around the site and sort of a difference, at least she sees, between compensation for breast cancer versus elevated rates in the area. There has

1	been no study of the workers themselves with
2	respect to breast cancer, I am told.
3	Anyway, so this is just to let the
4	public know as well as note that the Board
5	members have received this letter.
6	MEMBER LOCKEY: Just for the
7	record, there have been studies of Fernald.
8	And breast cancer rates were not increased.
9	CHAIRMAN ZIEMER: There has been a
10	study around Fernald.
11	MEMBER LOCKEY: Breast cancer rates
12	were not increased in Fernald.
13	CHAIRMAN ZIEMER: And Dr. Lockey is
14	reporting that what study was that?
15	MEMBER LOCKEY: I can bring it next
16	time. There were two articles that we used
17	when we looked at the Fernald compensation
18	program. No. Let me take that back. I'll
19	retract that statement. They did not look at
20	breast cancer because there were not enough
21	numbers there.

Yes.

CHAIRMAN ZIEMER:

22

Okay.

This

1	may be the concern that is being raised here.
2	MEMBER LOCKEY: I take that back.
3	There were not enough numbers. That is
4	correct.
5	CHAIRMAN ZIEMER: Okay. Thank you.
6	And let the record show that all of
7	the Board members have received a copy of this
8	letter, which comes from a former Fernald
9	worker.
10	MEMBER GRIFFON: Are you going to
11	put the letter into the transcript? No? It
12	won't become part of the transcript?
13	MR. KATZ: They can request it. I
14	am not going to read it into the transcript,
15	but it is available. I have made note of it
16	here. So anybody who would want it from the
17	public I would provide it to them.
18	CHAIRMAN ZIEMER: Thank you very
19	much.
20	I believe that that completes our
21	business for this Board meeting. I thank
22	everyone for their attendance and

1	participation. And we stand adjourned.
2	(Whereupon, the above-entitled
3	matter went off the record at
4	12:59 p.m.)
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	